 
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1, Open -Label Study to Evaluate the Effect of Itraconazole and Mefenamic Acid on 
the Single -Dose Pharmacokinetic Profile of Soticlestat in Healthy Participants
Study Identifier: TAK-935-1007
Compound: Soticlestat (TAK -935)
Sponsor: Takeda Development Center Americas, Inc  
95 Hayden Avenue
Lexington, MA 02421
Date: 23 August 2021
Version/Amendment 
Number:Final protocol
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 2 of 75
Protocol 23 August 2021
TABLE OF CONTENTS
1.0 STUDY SUMMARY ......................................................................................................7
2.0 STUDY SCHEMAT IC..................................................................................................13
3.0 SCHEDULE OF STUDY PROCEDURES .................................................................. .15
4.0 INTRODUCTI ON.........................................................................................................21
4.1 Background .............................................................................................. . ............21
4.1.1 Soticlestat (TAK -935) ..................................................................... ...............21
4.1.2 Itraconazo le ............................................................................. ......................22
4.1.3 Mefenamic aci d ................................................................... . ........................23
4.2 Rationale for the P roposed Study ......................................... . ................................23
4.3 Benefit/Risk Profile ............................................................ ....................................24
5.0 STUDY OBJECTIVES AND ENDPOINTS ..................... ............................................25
5.1 Hypothesis............................................................ .. ...............................................255.2 Study Objectives ................................................. ....................................................25
5.2.1 Study Primary Objectives ................... ............................................................25
5.2.2 Study Secondary Objective ........... . ................................................................25
5.3 Endpoints ................................... . .........................................................................25
5.3.1 Primary Endpoints ...........................................................................................25
5.3.2 Secondary Endpoints .. ....................................................................................26
6.0 STUDY DESIGN AND DE SCRIPTION .......................................................................26
6.1 Study Desi gn .. ... ....................................................................................................26
6.2 Dose Escalation .......................................................................................................286.3 Stopping Rules .........................................................................................................28
6.4 Rationale for Study Design, Dose, and E ndpoints .................................................... 28
6.4.1 Rationale of St udy Desi gn ...............................................................................28
6.4.2 Rationale for Dose...........................................................................................28
6.4.3 Rationale for Endpoints ...................................................................................29
6.4.4 Future Biomedical  Resear ch ............................................................................29
6.4.5 Critical Procedures Based on Study  Objectives: Timing of Procedures ............29
6.5 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters...............................................................................................................29
6.6 Study Beginning and End/Completion .....................................................................29
6.6.1 Definition of Begi nning of the Study ...............................................................29
6.6.2 Definition of E nd of the Study .........................................................................30CCI
CCIe
Property of Takeda: For Non-CommND DESD D
.. ... .....
latatioionn
ng RuleRul
ionale fonale
1rcial Use O.. . ...
..........
ntss.. ...y and Subject to the Applicable Terms of Use55
...2
..
...
...
.
...
..
..
.....
..
...
..ly and Subject to the Applicable Terms of Use133
...
.....
.
...
..
..
.
...
..
..
..
...
....
RaR
6.4.242
6.4.4
6Only
merc
Pr     Pr    ng Rg 
ionaleonale
1 RR
6.4.2.4.2
6.6.44   ..
.......        s e        s e33
...1515
.........
. .......
.. ...
......
.. ...
.. ... .
... ....
. .....
.. ... .
.... ...
. .... ...
.. ..
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 3of 75
Protocol 23 August 2021
6.6.3 Definit ion of Study  Completion ....................................................................... 30
6.6.4 Definit ion of Study  Discont inuat ion.................................................................30
6.6.5 Criteria for Premature Terminat ion or Suspension of the Study ........................ 30
6.6.6 Criteria for Premature Terminat ion or Suspension of a Site .............................. 30
7.0 SELECTION AND DISCONTINUAT ION/WITHDRAWAL OF PA RTICIPANTS .. .31
7.1 Inclusio n Cri teria.............................................................................................. ...... 31
7.2 Exclusio n Cri teria................................................................................... . ............ 31
7.3 Excluded Medicat ions, Supplements, Dietary  Products .......................... ................. 33
7.4 Diet, Fl uid, Act ivity.......................................................................... ......................34
7.4.1 Diet and Fluid .................................................................. ............................... 34
7.4.2 Activity........................................................................................................... 35
7.5 Criteria for Di scontinuati on or Wi thdrawal  of a Parti cipant ...................................... 35
7.6 Procedures for Discont inuat ion or Withdrawal o f a Parti cipant ................................ 36
7.7 Parti cipant Replacement ..................................... .. ................................................. 37
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 37
8.1 Clinical Study  Drug ................................. ..............................................................37
8.1.1 Clinical Study  Drug Labeling ........ ................................................................. 38
8.1.2 Clinical Study  Drug Inventory  and Storage ...................................................... 38
8.1.3 Clinical Study  Drug Blinding ........................................................................... 38
8.1.4 Randomization Code Creati on and Storage ...................................................... 38
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure .................................38
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................. 38
9.0 STUDY PROCEDURES ............................................................................................... 39
9.1 Administ rative Procedures ....................................................................................... 39
9.1.1 Inform ed Consent Procedure ............................................................................ 39
9.1.2 Inclusio n and Exclusio n................................................................................... 39
9.1.3 Medical History /Dem ography .......................................................................... 39
9.1.4 Concomitant Medications ................................................................................ 39
9.2 Clinical Procedures and Assessments ....................................................................... 39
9.2.1 Physical Exam .................................................................................................40
9.2.2 Height and Wei ght........................................................................................... 40
9.2.3 BMI ................................................................................................................. 40
9.2.4 Vital Signs....................................................................................................... 40
9.2.5 12-Lead ECG ................................ ................................................................... 40
9.2.6 Study  Drug Administration .............................................................................. 41
9.2.7 C-SSRS ........................................................................................................... 41
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 4of 75
Protocol 23 August 2021
9.2.8 AE Monitoring ................................................................................................ 42
9.2.9 Laboratory  Procedures and Assessments .......................................................... 42
9.3 Pharmacokinet ic Samples ........................................................................................ 44
9.3.1 Pharmacokinet ic Measurements ....................................................................... 44
9.3.2 Biomarker Measurem ents........................................................................... .. . 45
9.3.3 PGx Measurements ................................................................................... ...... 46
9.3.4 Confinement ................................................................................... . ............ 46
10.0 ADVERSE EVENTS .................................................................................. ................. 46
10.1 Definit ions and El ements of AEs ...................................................... ...................... 46
10.1.1 SAEs ............................................................................... ............................... 48
10.1.2 Speci al Interest AEs ......................................................................................... 49
10.2 AE Procedures ............................................................. .... ...................................... 49
10.2.1 Assigning Severit y/Intensit y of AEs ............... ................................................ 49
10.2.2 Assigning Causalit y of AEs ........................ .. ................................................. 50
10.2.3 Start Date .............................................. . ........................................................ 50
10.2.4 End Date .......................................... .............................................................. 51
10.2.5 Pattern of Adverse Event (Frequency) .............................................................. 51
10.2.6 Action Taken Wit h Study  Treatm ent................................................................ 51
10.2.7 Outcom e........................... . ............................................................................ 51
10.2.8 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and Abno rmal 
LFTs ........................ . ..................................................................................... 52
10.2.9 Safety Reporting to Invest igators, Institutional Review Board (IRB)s or 
Independent Ethics Committee (IEC)s, and Regul atory  Authori ties................. 54
11.0 STATISTICAL METHODS .......................................................................................... 54
11.1 Statistical and Analyt ical Plans ................................................................................ 54
11.1.1 Analysis Sets ................................................................................................... 54
11.1.2 Analysis of Demography  and Other Baseline Characterist ics........................... 55
11.1.3 PK Analysis ..................................................................................................... 55
11.1.4 PD Analysis ..................................................................................................... 55
11.1.5 Safety Analysis ................................................................................................ 55
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 57
11.3 Determinat ion of Sample Size .................................................................................. 57
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 57
12.1 Study -Site Moni toring Visit s................................................................................... 57
12.2 Protocol  Deviat ions.................................................................................................. 58
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 58
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 5of 75
Protocol 23 August 2021
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 58
13.1 IRB and/or IEC Approval ........................................................................................ 58
13.2 Parti cipant Inform ation, Inform ed Consent, and Participant Authorizat ion............... 59
13.3 Parti cipant Confident iality....................................................................................... 60
13.4 Publicat ion, Di sclosure, and Clinical Study  Reg istrati on Policy .......................... .. . 61
13.4.1 Publicat ion and Disclosure ........................................................................ ...... 61
13.4.2 Clinical Study  Registrati on............................................................. . ............ 61
13.4.3 Clinical Study  Resul ts Discl osure.................................................. ................. 62
13.5 Insurance and Co mpensation for Injury ............................................. ...................... 62
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......... ............................... 62
14.1 Administrative Informat ion...................................................................................... 62
14.1.1 Study  Contact Informat ion................................... .... ...................................... 62
14.1.2 INVESTIGATOR AGREEMENT .................. ................................................ 63
14.1.3Study -Related Responsibilit ies.................... .. ................................................. 64
14.1.4 List of Abbreviat ions............................ . ........................................................ 64
15.0 DAT A HANDLING AND RE CORD KEEPING ........................................................... 66
15.1 CRFs (El ectronic and Paper) .................. ................................................................. 66
15.2 Record Retention ..................................................................................................... 66
16.0 REFERENCES ............................... . ............................................................................ 67
17.0 APPENDICES ....................... . . . ................................................................................. 68
LIST OF IN -TEXT TABLES
Table 2.a Study  Design for Part 1 ...................................................................................... 13
Table 2.b Dose Regimens for Study  Drugs in Part 1 .......................................................... 13
Table 2.c Study  Design for Part 2 ...................................................................................... 14
Table 2.d Dose Regimens for Study  Drugs in Part 2 .......................................................... 14
Table 3.a Part 1: DDI with Itraconazole ............................................................................. 15
Table 3.b Part 2: DDI with Mefenamic Acid ...................................................................... 18
Table 7.a Excluded Medicat ions, Supplements, and Dietary  Products ................................ 34
Table 9.a Primary Specimen Collections ........................................................................... 44
Table 10.a Takeda Medically Significant AE List ................................................................ 49
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 6of 75
Protocol 23 August 2021
LIST OF APPENDICES
Appendix A Responsibilit ies o f the Invest igator ..................................................................... 68
Appendix B Elements of the Participant Informed Consent .................................................... 70
Appendix C Invest igator Consent to the Use of Personal Information .................................. . 73
Appendix D Pregnancy and Contraception ............................................................................. 74
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 9of 75
Protocol 23 August 2021
Duration of Treatments:
Part 1: DDI with Itraconazole
Soticlestat: Single -dose on Day 1 Period 1 and 
single -dose on Day 5 Period 2
Itraconazole: QD on Days 1 to 11 Period 2
Part 2: DDI with Mefenamic acid
Soticlestat : Single -dose on Day 1 Period 1 and 
single -dose on Day  2 Period 2
Mefenamic acid: Q6H on Days 1 to 7 Period 2Planned Study Duration :
Part 1: DDI with Itraconazole
Approximately 52 days including screening period and 
follow -up.
Part 2: DDI with Mefenamic acid
Approximately 48 days including screening pe riod and 
follow -up.
Criteria for Inclusion:
Participants must fulfill the following inclusion criteria before the first dose to be eligible for participation in the stud y: 
1.Healthy , adult, male or female of non -childbearing potential ( Appendix D), 19- 55years of age, inclusive, at 
screening.
2.Male participants agrees to comply with any applicable contraceptive requirements of the pr otocol as detailed in 
Appendix D.
3.Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2at screening. 
4.Continuous non -smoker who has not used nicotine -contain ing products for at least 90 days prior to the first 
dosing.
5.Medically healthy with no clinically significant medical histor y, physical examination, laboratory profiles, vital 
signs or ECGs, as deemed by the Investigator or designee.
Supine blood pressure is ≥90/40 mmHg and ≤140/90 mmHg at screening;
Supine pulse rate is ≥45 bpm and ≤100 bpm at screening;
QTcF is ≤450 msec (males) or ≤470 msec (females) and ECG findings considered normal or not clinically 
significant by the Investigator or designee at scree ning;
Estimated creatinine cl earance ≥80 mL/min at screening;
Liver function tests including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤1.5 X 
the upper limit of normal (ULN) at screening and check -in.
6.Able to swallow multiple tabl ets.
7.Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the 
protocol.
Criteria for Exclusion:
Participants must not be enrolled in the study if they meet any of the following criteria before the first dose of study 
drug:
1.Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or 
expected during the conduct of the study.
2.Histor y or presence of clinically significant medical or psychiatric condition or disease in the opinion of the 
Investigator or designee.
3.Histor y or presence of gastritis, gastrointestinal (GI) tract, gastric bypass surgery, or hepatic disorder or other 
clinical condition which, in the opinion of the Investigator or designe e, may  affect the absorption, distribution, 
metabolism, or elimination of study drugs.
4.Histor y or presence of any of the following, deemed clinically significant by the investigator:
epilepsy , seizure, or convulsion, tremor or related symptoms; 
arrhy thmia s or other cardiovascular disorder;
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 10of 75
Protocol 23 August 2021
GI disorder (eg peptic ulcer disease, gastroesophageal reflux disease, impaction, chronic constipation, 
inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, 
bowel o bstruction, bariatric surgery, cholecystitis, intestinal ulceration or inflammation);
GI bleeding or perforation;
recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding);
known bleeding or coagulation disorders; 
history  of thromboembolic events;
hyperkalemia.
5.Histor y or presence of cataracts or other clinically significant vision disturbances. 
6.Histor y of any  illness that, in the opinion of the Investigator or designee, might confound the results of the study 
or poses an additional risk to the participants by their participation in the study.
7.Histor y or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
8.Histor y or presence of hypersensitivity or idiosyncratic reaction to the stu dy drugs or related compounds.
9.Part 2 o nly: Known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with 
other CYP2C9 substrates. 
10.Any positive responses on the C-SSRS that in the clinical judgement of the Investigator has a risk of suicide or has 
made a suicide attempt in the previous 12 months prior to the first dosing.
11.Female participants of childbearing potential.
12.Female participants with a positive pregnancy test at screening or check -in or who is lactating.
13.Positive urin e drug or alcohol results at screening or check -in.
14.Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or 
hepatitis C virus (HCV).
15.Unable to refrain from or anticipates the use of:
Any drug, including prescription and non -prescription medications, herbal remedies, or vitamin supplements 
within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the 
participant has been on the same stable dose for the immediate 3 months prior to first dosing. 
Any drugs known to be significant inducers of CYP3A, CYP2C9 (Part 2), CYP2C19, UGT1A9 or UGT2B4 
enzymes and/or P gp, including St. John’s Wort, within 28 days prior to the first dosing. Appropriate sources 
(eg, Flockhart Tab leTM) will be consulted to confirm lack of PK/pharmacodynamics interaction with study 
drug.
16.Histor y of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately 
equivalent to the following: beer [354 mL/12 oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).
17.Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg 
of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per da y.
18.Has been on a diet incompatible with the on -study diet, in the opinion of the Investigator or designee, within the 
30days prior to the first dosing and throughout the study.
19.Donation of blood or significant blood loss within 56 days prior to the first dosing.
20Plasma do nation within 7 days prior to the first dosing.
21.Participation in another clinical study within 30 days or 5 half -lives prior to the first dosing. The 30 -day window 
or 5 half -lives will be derived from the date of the last blood collection or dosing, whichever is later, in the 
previous study to Day 1 of Period 1 of the current study.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 11 of 75
Protocol 23 August 2021
Main Criteria for Evaluation and Analyses:
Primary Endpoints:
The following PK parameters will be analyzed for soticlestat, when administered alone and when co-administered 
with itraconazole (Part 1) or mefenamic acid (Part 2):
!Maximum observed concentration (C max)
!Area under the concentration-time curve from time 0 to infinity, calculated using the observed value of the 
last quantifiable concentration (AUC ∞)
!Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration 
(AUC last)
!Time of first occurrence of C max (tmax)
Secondary Endpoints: 
!Number of participants with at least one TEAE
!Incidence of clinically significant abnormal values for laboratory evaluations, vital signs, ECG parameters 
and C-SSRS.
Statistical Considerations:
Pharmacokinetics:For each part, natural log (ln)-transformed AUC
last, AUC ∞, and C maxdata will be analyzed using a linear mixed effects 
model, separately. The model will include treatment (soticlestat with and without itraconazole/mefenamic acid) as a fixed effect and participant as a random effect. The point estimates and the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) for soticlestat with versus without itraconazole/mefenamic acid will be calculated.
The following treatment contrast will be evaluated separately: itraconazole + soticlestat relative to soticlestat alone 
and mefenamic acid + soticlestat relative to soticlestat alone. 
Safety:
AEs will be tabulated. Summary statistics for vital signs, safety 12-lead ECGs, C-SSRS and clinical laboratory 
assessments will be computed and provided.CCI
CCIe
Property oety:ety
AEsAEs
artySf Takeda: For Non-Colog (ln)g( l n
The modThe m
d particip c
ean ration rati
wing trewing t
efenamicefenamCoo the Applicable Terms of Usef the
ratioa
vitaoo
t to the Applicable Terms of Useue oue o
ncenncen
ionsnsff
pepeCommercial Use Only and Subject t
of TI
Pr  Pr  SafetySafety
AEAE   log (og
The moThe m
participartic
ean ratian rati
wing trwing t
efenamefenam  I     se     see of the of th
entratientra
ons, vits, vi
         
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 12 of 75
Protocol 23 August 2021
CCI
e
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Uset to the Applicable Terms of Us
Pr     Pr              s e         s e     s     s
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 13 of 75
Protocol 23 August 2021
2.0 STUDY SCHEMATIC
Table 2.a Study Design for Part 1
SPeriod 1 Period 2
FUC-I and 
Predose 
AssessmentsSoticlestat 
Dosing, PK 
Sampling 
and Study 
AssessmentsPK 
Sampling 
and Study 
AssessmentsItraconazole 
Dosing and 
Study 
AssessmentsCo-administration 
(Itraconazole and 
Soticlestat), PK 
Sampling and 
Study 
AssessmentsItraconazole 
Dosing, PK 
Sampling 
and Study 
AssessmentsStudy Exit c
(PK 
Samping and 
Study 
Assessments)
Within 
28 days 
prior to 
first 
dosingDay -1 Day 1 Day 2 – 5 aDay 1 a- 4 Day 5 Day 6 - 11 Day 1215 (± 2) 
days 
following 
last 
soticlestat 
dose
---------------------------Confinement b------------------------------------- Contact
aDay 1 of Period 2 will also be considered Day 5 of Period 1.
bParticipants will start the confinement on Day -1 of Period 1 and remain confined until Day 12 of Period 2.
cStudy Exit is defined as the end of last treatment period.
Abbreviations: C-I = Check-in, FU = Follow-up, PK = Pharmacokinetic, S = Screening.
Table 2.b Dose Regimens for Study Drugs in Part 1
Study Drug Dose Dose Regimen Number of Days on Study Drug
Soticlestat 300 mg Single dose, oral Day 1 Period 1 and Day 5 Period 2
Itraconazole (oral solution) 200 mg (10 mL of 20 mg/mL oral 
solution)QD, oral Days 1 through 11 Period 2CCI CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usems
ng and ng a
Studu
ssessmentssessmee T
6 -11pl
tAp
----------ttt
nfined untnfined 
ic, Sc, S=ScSje
Drugs inugs 
se
of 20 mgof 20 m
solution)utionia
meial U
Pr     Pr          fined uined u      s e      s eg and g and 
udy udy 
sessmesessme 
-1111
------------
c, Sc, S==SS
rugs irugs i
 
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 14 of 75
Protocol 23 August 2021
Table 2.c Study Design for Part 2
SPeriod 1 Period 2
FUC-I and 
Predose 
AssessmentsSoticlestat 
Dosing, PK 
Sampling, 
and Study 
AssessmentsPK 
Sampling 
and Study 
AssessmentsMefenamic 
Acid Dosing 
and Study 
AssessmentsCo-administration 
(Mefenamic Acid 
and Soticlestat),
PK Sampling, and 
Study 
AssessmentsMefenamic 
Acid 
Dosing, PK 
Sampling, 
and Study 
AssessmentsStudy Exit c
(PK 
Sampling 
and Study 
Assessments)
Within 
28 days 
prior to 
first 
dosngDay -1 Day 1 Day 2 – 5 aDay 1 aDay 2 Day 3 - 7 Day 815 (± 2) 
days
following 
last 
soticlestat 
dose
---------------------------Confinement b------------------------------------- Contact
aDay 1 of Period 2 will also be considered Day 5 of Period 1 
bParticipants will start the confinement on Day -1 of Period 1 and remain confined until Day 8 of Period 2.
cStudy Exit is defined as the end of last treatment period.
Abbreviations: C-I = Check-in, FU = Follow-up, PK = Pharmacokinetic, S = Screening.
Table 2.d Dose Regimens for Study Drugs in Part 2
Study Drug Dose Dose Regimen Number of Days on Study Drug
Soticlestat 300 mg Single dose, oral Day 1 Period 1 and Day 2 Period 2
Mefenamic acid 
(capsules)500 mg (2 x 250 mg capsules) Once, oral Initial dose - Morning of Day 1 of Period 2
250 mg (1 x 250 mg capsule) Q6H, oralAll subsequent doses following the morning dose 
on Day 1 of Period 2 – Days 1 through 7 of 
Period 2CCI CCIe
Property of Takeda: For Non-Commercial apsules)psules)Use Only and Subject to the Applicable Terms of UseFU
ts))o
c
A
---o
untinti
ScrSc
in P
DosD
SsUal Use Only and Subject to the Applicable Terms of Usefff
g
udy udy
smemT
3 -7lip
---t
fined
c, SSe
rugsg
esUal
0mg capmg crc
omal U
Pr     Pr              s e         s eFF
dy y 
ments)ments)
-77
---------
ned unned un
SS==ScS
ugs ings in
DoD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 17of 75
Protocol 23 August 2021
CONFIDENTIALg All assessments will be performed after participants have rested for at least 5 minutes in the supine position.
h Samples for serum chemistry will be obtained following a fast of at least 8 hours, however, in case of dropouts or rechecks, participants may not have fasted for 8 hours prior to 
the serum chemistry sample is taken.
i To be performed within 24 hours prior to dosing of soticlestat.
j At screening, the C -SSRS Baseline/Screening version will be administered; at all other time points, the Since Last Visit version will be administe red.
k Soticlestat will be administered following an overnight fast of at least 10 hours . Fasting will continue for at least 4 hours postdose.
l To be performed prior to dosing.
m To be performed prior to early termination from the study.
n The CRU will contact all participants (including participants who terminate the study early) 15 (±2) days after the last soti clestat administration by telephone or other methods 
per CRU standards dose to determine if any AEs have occurred and/or any concomitant medications were taken since the last stu dy visit.
o On Days 1 to 4 and Days 6 to 11, participants will receive 200 mg itraconazole QD as an oral solution on an empty stomach (no food from 1 hour before until 2 hours after 
dosing). On Day 5 participants will receive 200 mg itraconazole QD as an oral solution on an empty stomach (no food from at l east 10 hours before until at least 4 hours after 
dosin g).
Abbreviations: ♀ =Females, AE =Adverse events, BP =Blood pressure, C -I =Check -in, C -SSRS = Columbia -Suicide Severity Rating Scale , Chem =Chemistry, 
Coag =Coagulation, ConMeds =Concomitant medication, COVID -19 = coronavirus 2019, CRU =Clinical research unit, ECG =Electrocardiogram, ET =Early Termination, 
FSH =Follicle -stimulating hormone, FU =Follow- up, Hem =Hematology, HIV =Human immunodeficiency virus, PK =Pharmacokinetics, PR =Pulse rate, Preg =Pregnancy, 
RR=Respiratory rate, S = Screening, T =Temperature, UA =Urinalysis.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 20of 75
Protocol 23 August 2021
CONFIDENTIALj At screening, the C -SSRS Baseline/Screening version will be administered; at all other time points, the Since Last Visit version will be administ ered.
k After an overnight fast of at least 10 hours (Day 1 of Period 1) or 6 hours (Day 2 of Period 2), soticlestat will be ad ministered. Fasting will continue for at least 4 hours postdose .
l To be performed prior to dosing.
m To be performed prior to early termination from the study.
n The CRU will contact all participants (including participants who terminate the study early) 15 (±2 ) days after the last soticlestat administration by telephone or other methods 
per CRU standards to determine if any AEs have occurred and/or any concomitant medications were taken since the last study vi sit.
o Participants will receive mefenamic acid QID on Days 1 to 7. The initial dose of 500 mg will be administered under fed conditions in the morning of Day 1 and all subsequent 
doses will be 250 mg administered Q6H under fed conditions ( except for the morning dose on Day  2; no food from 6 hours before unti l 4 hours after dosing ) through Day  7. 
Participants should not lie down for at least 10 minutes after taking mefenamic acid.
Abbreviations: ♀ =Females, AE =Adverse events, BP =Blood pressure, C -I =Check -in, C -SSRS = Columbia -Suicide Severity Rating Sc ale,Chem =Chemistry, 
Coag =Coagulation, ConMeds =Concomitant medication, COVID -19 = coronavirus 2019, CRU =Clinical research unit, ECG =Electrocardiogram, ET =Early Termination, 
FSH =Follicle -stimulating hormone, FU =Follow- up, Hem =Hematology, H IV=Human immunodeficiency virus, PK =Pharmacokinetics, PR =Pulse rate, Preg =Pregnancy, 
Q6H = every 6 hours, QID = four times a day, RR =Respiratory rate, S =Screening, T =Temperature, UA =Urinalysis.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 21 of 75
Protocol 23 August 2021
4.0 INTRODUCTION
4.1 Background
4.1.1 Soticlestat (TAK-935)
Soticlestat is a potent and selective cholesterol 24 Shydroxylase (CH24H) inhibitor currently in 
development as an oral adjunct to standard of care (SOC) therapy for the treatment of rare pediatric 
epilepsies referred to as Developmental and Epileptic Encephalopathies (DEE) which is a cluster 
of pediatric epilepsy syndromes and includes Dravet Syndrome (DS) and Lennox Gastaut 
Syndrome (LGS). Epilepsy is linked to a dys regulation in glutamatergic signaling brought upon by 
an over-activation of CH24H. This enzyme is pre dominantly expressed in neurons and involved in 
the homeostasis of brain cholesterol by converting it to 24 S-hydroxycholesterol, a polar metabolite 
capable of passing the blood-brain barrier via lipoproteins. 
Soticlestat is a first-in-class therapeutic candidate  that has the potential to control seizures in 
treatment-resistant patients with epilepsy by modulating reactive astrocytes and reducing 
over-activated glutamate signaling in neurons. This mechanism of action is thought to clinically 
manage seizures by reducing seizure frequency and se verity as well as brain damage and cognitive 
deficits that are pathological sequelae of the epileptogenic process but also other conditions where 
excessive glutamatergic signaling activity drives the pathology.
CCI
CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usently 
re pe
ch ish
x Ga
ing bng 
euro
este
tentien
ve ae
nisms
rityy
enicn
he ppOnly and Subject to the Applicable Terms of Useurrenrre
ff raraff
whiwh
nnoxox
gnalna
in nin n
choholl
e pote po
eactieac
chanhan
everve
ptogt
es thes th
of Takeda: For Non-Commercial Use O
Property oPr  Pr       
Pr  Pr          s e        s errentlyrrent
 rare prare 
which which 
nox Gnox G
nalingaling
n neurn neu
hoholestlest
potenpoten
activeactive
hanismhanis
veritverityy
togenitogeni
s the pthe 
   
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 23 of 75
Protocol 23 August 2021
4.4 hours (with food) postdose. Itraconazole is highly protein bound (> 99%) and distributes 
extensively into human tissue [3]. 
Itraconazole is extensively metabolized, predominan tly by the CYP3A4 enzymes, and is known to 
undergo enterohepatic recirculation. Hydroxyitraconazole is the major metabolite and shows 
antifungal activity equal to that of the parent [3]. Itraconazole is a competitive CYP3A4 inhibitor, 
and following multiple dosing, ~40% of overall CYP3A inhibition is attributed to 
hydroxyitraconazole [4]. 
The terminal t½ of itraconazole typically range s from 16 - 28 hours after a single dose and 
increases to 34 - 42 hours with multiple dosing, due  to non-linear PK. Itraconazole is mainly 
excreted as inactive metabolites in the urine (35%) and feces (54%) [3]. 
Overall, itraconazole is associated with infrequent mild adverse reactions. The exceptions are rare 
cases of hepatotoxicity, hearing loss (transient or permanent, but the hearing loss usually resolves 
upon treatment cessation), and QT prolongation [3]. 
Refer to the full prescribing information for more detailed background on itraconazole [3].
4.1.3 Mefenamic acid
Mefenamic acid is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic 
properties. It is rapidly absorbed after oral admin istration with peak plasma levels attained within 2 
to 4 hours and has a short half-life of a pproximately 2 hours. Following multiple doses, plasma 
levels have shown to be proportional to dose with no evidence of drug accumulation. In 
participants receiving 1 gram dose Q6H, steady-state concentrations were reached on the second 
day of dosing, consistent with the short half-life [5].
Mefenamic acid undergoes glucuronidation and is also metabolized by CYP2C9 to 
3-hydroxymethyl mefenamic acid that may undergo further oxidation to a 3-carboxymefenamic 
acid metabolite. The activity of these metabolites has not been studied [5].
Approximately fifty-two percent of a mefenamic acid dose is excreted into the urine primarily as 
glucuronides of mefenamic acid (6%), 3-hydroxy mefenamic acid (25%) and 3-carboxymefenamic 
acid (21%). The fecal route of elimination accounts for up to 20% of the dose, mainly in the form 
of unconjugated 3-carboxymefenamic acid [5].
Refer to the full prescribing information for more detailed background on mefenamic acid [5].
4.2 Rationale for the Proposed Study
CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usen to o
s 
nhibitornhi
gle dose le dos
nazoazole i
ons. Thns T
he hearihe he
backgrockgr
ry drugry dru
nistrationistrati
ximatelymate
dose withose w
H, steadH, stea
hort halort ha
curonidauroni
c acid thacid 
itytyi ofofythf
two percwo pe
fenamienam
e fecal re fecal
ated 3 -c
the full the fu
RaRa
perty of T
Pr    Pr    fefe
e fecal e fecal
ated 3ed 3
the fulthe fu
RR
            s e         s eto o 
nhibitohibito
e dosee dose
azoazolele
ns. Tns. T
e heare he
ackgroackgr
y drugy drug
istratistra
matelmate
ose wise wi
steastea
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 24 of 75
Protocol 23 August 2021
Itraconazole is selected for Part 1 as it is a well characterized, competitive, strong inhibitor of 
CYP3A4 and a potent P-gp inhibitor. Moreover it is considered a strong index inhibitor of CYP3A 
as per the Food and Drug Administration (FDA): Drug Development and Drug Interactions: Table 
of Substrates, Inhibitors, and Inducers [6]. It is also among choices of inhibitors of P-gp; as 
soticlestat is a weak substrate of P-gp, co-administration of itraconazole will also inform strategies 
for management of potential DDI with P-gp inhibitors. 
Mefenamic acid is proposed for Part 2 as a UGT1A9 inhibitor. In a clinical DDI study with 
ertugliflozin, a medication used to treat type 2 diabetes with metabolism and elimination 
properties similar to soticlestat, mefenamic acid was used as a UGT1A9 inhibitor. Ertugliflozinis 
mainly metabolized by glucuronidation (88%), predominantly by UGT1A9 with minor 
contributions from UGT2B4/2B7, whereas oxidative metabolism (10%) and renal elimination of 
unchanged drug (2%) are minor. Co-administration of ertugliflozin with mefenamic acid led to a 
51% increase in ertugliflozin exposure (ratio of the area under the plasma concentration–time 
curves (AUCR) = 1.51) [8]. Similar results were observed when mefenamic acid was used as a 
UGT1A9 inhibitor with dapagliflozin, another medication used to treat type 2 diabetes and mainly 
metabolized by UGT1A9. [7].
4.3 Benefit/Risk Profile
The dose of 300 mg soticlestat is the recommended phase 3 dose [2] and will be administered as a 
single-dose in this study. In addition, doses up to 1350 mg were administered in healthy 
participants and was found to be safe and well tolerated.
The doses of itraconazole and mefenamic acid administered in this study are not anticipated to 
induce any potential risk or benefit to participants participating in this study, as they are being 
administered according to the dosing reco mmendations presented  in the labelling.CCI
e
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useracterizec
t is consis con
A): Drug): Drug
t iis also
adminiadm
h Ph P--gp ig
Partrt2 as2 a
d to tread to tre
stat, meat, m
lucuroncuro
GT2B4/GT2B
%) are m%) are
For Nertuglifertug
R) 1.5
inhibitohibito
lized byized b
3 BeB
The dhe
sinsid Subject to the Applicable Terms of Us
Pr    Pr    %
ertugertug
R))==1
inhibitohibito
lized bized b
3 BB
The The
sisi     acterizcteriz
is conis con
): Dru): Dru
iis alss als
adminadmi
gpsese
      s      s
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 25 of 75
Protocol 23 August 2021
The inclusion and exclusion criteria, screening, and safety monitoring practices employed by this 
protocol (ie, 12-lead ECG, vital signs, clinical laboratory tests, AE questioning, C-SSRS, and 
physical examination) are adequate to protect the participant’s safety and should detect all TEAEs. 
In addition, in Part 2, participants who are known or suspected to be poor CYP2C9 metabolizers 
based on previous history/experience with other CYP2C9 substrates will be excluded as they may 
have abnormally high plasma levels due to reduced metabolic clearance. 
There will be no direct health benefit for study participants from r eceipt of study drugs. An indirect 
health benef it to the healthy par ticipants enrolled in this study is the free medical tests received at 
screening and during the study.
5.0 STUDY OBJECTIVES AND ENDPOINTS5.1 Hypothesis
Not applicable. 
5.2 Study Objectives
5.2.1 Study Primary Objectives
!Part 1: To assess the effect of multiple-dose administration of itraconazole, a strong CYP3A 
inhibitor, on the single-dose PK of soticlestat.
!Part 2: To assess the effect of multiple-dose administration of mefenamic acid, a strong 
UGT1A9 inhibitor, on the single-dose PK of soticlestat.
5.2.2 Study Secondary Objective
!Part 1 and Part 2: To evaluate the safety and tolerability of soticlestat following a single oral 
dose in healthy adult participants with/without strong CYP3A and UGT1A9 inhibitors.
5.3 Endpoints
5.3.1 Primary Endpoints
The following PK parameters will be analyzed for soticlestat, when administered alone and when 
co-administered with itraconazole (Part 1) or mefenamic acid (Part 2):
!Maximum observed concentration (C
max)
!Area under the concentration-time curve from time 0 to infinity, calculated using the observed 
value of the last quantifiable concentration (AUC ∞)
!Area under the concentration-time curve from time 0 to the time of the last quantifiable 
concentration (AUC last)
!Time of first occurrence of C max(tmax)CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Uses. 
ers r
ey maym y
gs. An igs. An
 tests retests 
dministr s
at.at
dose addose
se PK oeP K
tiveve
te e ththe se
ticipantscipan
dpoints n
Primaim
oolllwinw
-admindmin
M
!For Non-Com
Pr    Pr    pointsoin
PrimPrim
oollollowiw
-adminadmin
!!M           s e         s ers rs 
y may ma
s. An s. An
tests tests 
ministminis
t.t.
dose adose
e PK  PK 
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 26 of 75
Protocol 23 August 2021
5.3.2 Secondary Endpoints 
!Number of participants with at least one TEAE.
!Incidence of clinically significant abnormal values for laboratory evaluations, vital signs, ECG 
parameters and C-SSRS.
6.0 STUDY DESIGN AND DESCRIPTION
6.1 Study Design 
This is a 2 part, open-label, DDI study to evaluate the effect of a strong CYP3A inhibitor, 
itraconazole (Part 1), and a strong UGT1A9 inhibitor, mefenamic acid (Part 2), on the single-dose 
PK of soticlestat (TAK-935) in healthy adult participants. 
Each part will be conducted independently as a 2-period, fixed-sequence design. Study schematics 
of the study design and dose regimen are shown in Table 2.a, Table 2.b, Table 2.c andTable 2.d.  A 
schedule of assessments is shown in Schedule of Study Procedures (Section 3.0).
The two study parts may be conducted concurrently. Participants can only participate in one study 
part. 
Part 1: DDI with itraconazole
Participants will be screened within 4 weeks (28 days) prior to the first dosing (Day -28 to first 
dosing on Day 1 of Period 1). Upon completion of screening, qualified participants will be CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseECG C
ND DESD DE
nn--lalabel,be
rt 1), andrt 1), an
tat (TAt (TA
will be l be
study deudy d
edule ofdule o
The twotw
part.partmercial Use Only and Subject to the Applicable Ter
Pr    Pr    rt 1), rt 1), 
tat (TAat (TA
will bewill be
study dudy d
edule oedule o
The twThe tw
parpar  se  seCG CG 
               
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 27 of 75
Protocol 23 August 2021
admitted to the study site on Day -1 of Period 1 a nd will remain confined until completion of study 
procedures on Day 12 of Period 2. 
In Period 1, on Day 1, participants will receive a single oral dose of 300 mg soticlestat 
. Blood samples for the PK of soticlestat  will be collected at 
scheduled time points from predose through 96 hours postdose. There will be a washout period of 
exactly 4 days between soticlestat dose in Period 1 and the first itraconazole dose in Period 2.
In Period 2, from Days 1 to 11, participants will receive a QD oral dose of 200 mg itraconazole. On 
the morning of Day 5, participants will receive a single oral dose of 300 mg soticlestat 
 co-administered with the single oral dos e of 200 mg itraconazole. Blood samples for 
the PK of soticlestat will be collected at scheduled time points from predose on 
Day 5 through 168 h
Safety and tolerability will be assesse d throughout the study by TEAEs, clinical laboratory
evaluations, physical examinations, C-SSRS, 12-lead ECGs, and vital signs.
After discharge, the CRU will contact all participants (including participants who terminate the 
study early) 15 (±2) days after the last soti clestat administration by telephone or other methods per 
CRU standards to determine if any AEs have o ccurred and/or any concomitant medications were 
taken since the last study visit. If clinically significant findings are observed upon discharge, 
participants may return to the CRU for re -evaluation per Investigator’s discretion.
Part 2: DDI with mefenamic acid
Participants will be screened within 4 weeks (28 days) prior to the first dosing (Day -28 to first 
dosing on Day 1 of Period 1). Upon completion of screening, qualified participants will be 
admitted to the study site on Day -1 of Period 1 a nd will remain confined until completion of study 
procedures on Day 8 of Period 2. 
In Period 1, on Day 1, participants will r eceive a single oral dose of 300 mg soticlestat 
. Blood samples for the PK of soticlestat  will be collected at 
scheduled time points from predose through 96 hours postdose. There will be a washout period of 
exactly 4 days between soticlestat dose in Period 1 and the first mefenamic acid dose in Period 2. 
In Period 2, participants will receive mefenamic acid QID (Q6H) from Day 1 to 7. The initial oral 
dose on the morning of Day 1 will be 500 mg and all subsequent oral doses will be 250 mg. On the 
morning of Day 2, participants will r eceive a single oral dose of 300 mg soticlestat 
 co-administered with the morning dose of 250 mg mefenamic acid. Blood samples for the 
PK of soticlestat will be collected at scheduled time points from predose on 
Day 2 through 144 hours postdose. 
Safety and tolerability will be assesse d throughout the study by TEAEs, clinical laboratory
evaluations, physical examinations, C-SSRS 12-lead ECGs, and vital signs. 
After discharge, the CRU will contact all participants (including participants who terminate the 
study early) 15 (±2) days after the last soticlestat administration by telephone or other methods per 
CRU standards to determine if any AEs have o ccurred and/or any concomitant medications were CCICCI
CCI
CCI
CCI
CCICCI
CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Termsperiperi
erioio
tracrac
clestat lestat
e. BloodBlo
e pointspoint
EAEs, cEAEs
d vital sd vit
uding paing p
tration btration
d and/orand
cant findtf
ation peion p
weeks (weeks
n comcomplpmmmm
-1 of P of P
d 2. 2. 
ticipantcipan
ples fples f orfff
nts frots fro m
etween setween
participaci
he morni orn
g of DaD
coof Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useod o
d2 .2
onaoof Use
K of sof
Dayay2y
SaSso
abCC
fT
Pr    Pr    etweeetwee
participartici
he morne morn
g og of Df D
 co co
K of sof 
DayDay
SS         s e         s eeriod eriod 
riod 2od 2
raconracon
lestat estat 
BlooBloo
pointoint
AEs, cAEs
d vitald vita
ding pding p
rationation
and/oand/
ant finnt fin
ion pion p
eeks eksCC
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 28 of 75
Protocol 23 August 2021
taken since the last study visit. If clinically significant findings are observed upon discharge, 
participants may return to the CRU for re -evaluation per Investigator’s discretion.
6.2 Dose Escalation
Not applicable. 
6.3 Stopping Rules
Not applicable.
6.4 Rationale for Study Design, Dose, and Endpoints
6.4.1 Rationale of Study Design 
The study design of each part is an open-label, 2-period, fixed sequence to evaluate both the effect
of CYP3A4 (Part 1) and UGT1A9 (Part 2) inhibitors. The fixed-sequence design selected to allow 
for simple management of washout period, improves feasibility, and prevents any carryover effect 
of the study treatment. It also has the advantage of reducing the residual variability since 
participants act as their own control. There will be a washout period of exactly 4 days between the 
soticlestat dosing alone (Day 1 of Period 1) and the first itraconazole dose or mefenamic acid dose 
(Day 1 of Period 2) and it is considered s ufficient to prevent carryover effect of the treatment.
6.4.2 Rationale for Dose 
CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usequence tuence
dd-sequesequ
ilitty,yana
cing the ing the
washout sho
e first itrst
nt to prent to p
operty of Takeda: For Non-Commercial UsPrPr                s e         s euence uence
sequsequ
litity,y,ana
ng theng the
ashouashou
first itfirst i
nt to pnt to p
 
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 29 of 75
Protocol 23 August 2021
6.4.3 Rationale for Endpoints
6.4.3.1 Pharmacokinetic Endpoints
The PK endpoints are standard for this type of study.
6.4.3.2 Safety Endpoints
The key safety endpoints are typical for phase 1 studies and will be assessed through monitoring of 
AEs, vital signs, 12-lead ECGs, clinical laboratory evaluations, C-SSRS, and physical 
examinations.
6.4.5 Critical Procedures Based on Study Objectives: Timing of Procedures 
For this study, the critical component is th e blood collection for plasma concentrations of 
soticlestat , and is to be collected as close to the scheduled times defined in this 
protocol as possible.
6.5 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
The dose and administration of the study drugs to  any participant may not be modified. 
Unscheduled procedures might be performed for safety reasons. If necessary, a participant may be 
discontinued for the reasons described in Section 7.5and Section 7.6.
6.6 Study Beginning and End/Completion
6.6.1 Definition of Beginning of the Study
The beginning of the study will be defined as the beginning of the screening (ie, signing of the 
ICF) of the first participant.CCI
CCIe
Property of Takeda: Forsible.ible.
StudydyD
Paraar
e dose adose
Unschech
iscscNon-Commercial Use Only and Subject to the Applicable Terms of Useh monitomoni
hysical hysica
dures Bures
titical cocal cmmercial Use Only and Subject to the Ap
or No
Pr    Pr    sible.ible.
Studytudy
ParPar
e dosedose
UnschUnsch
didiss    se   semonimoni
ysical ysical
             
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 30of 75
Protocol 23 August 2021
6.6.2 Definition of End of the Study
The end o f study  is defined as the date of the last scheduled study  procedure as outlined in the 
Schedule of Study  Procedures (Section 3.0).
6.6.3 Definition of Study Completion
Study  com pletion is defined as the date when the last fo llow-up visit for the last participat ing 
participant in the study  is completed.
This t ime period may change in the event that the study is terminated early or the last par ticipant is 
lost to foll ow-up. 
6.6.4 Definition of Study Discontinuation
Celeri on reserves the ri ght to terminate the study  in the interest of participant’s welfare.
The Sponsor reserves the right to suspend or terminate the study  at any  time for any  reason.
6.6.5 Criteria for Premature Termination or Suspension of the Study
The study  will be com pleted as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
New informat ion or other eval uation regarding the safet y or efficacy  of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for participants participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromises the abilit y to achieve 
the primary  study  objectives or compromises participant safet y.
6.6.6 Criteria for Premature Termination or Suspension of a Site
6.6.6.1 Criteria for Premature Termination or Suspension
A study  site may beterminated prematurely  or suspended if the site (including the Investigator) is 
found in significant vio lation of GCP, the study  protocol , or contractual agreement; if the site 
(including the Investigator) is unable to ensure adequate performance of the s tudy; or as otherwise 
permitted by  the contractual  agreement.
6.6.6.2 Procedures for Premature Termination or Suspension
In the event that the sponsor, an Institutional Review Board (IRB)/ Independent Ethics Co mmittee
(IEC) , or a regulatory  authori ty elects to term inate or suspend the participat ion of an 
investigat ional site, a study -specific procedure for early  terminat ion or suspensio n will be 
provi ded by the sponsor; the procedure will be fo llowed by applicable investigational site(s) 
during the course of termina tion or study  suspension.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 31of 75
Protocol 23 August 2021
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF PARTICIPANTS
7.1 Inclusion Criteria 
Parti cipants m ust fulfill the following inclusio n criteri a before the first dose to be eligible for 
participat ion in the study:
1.Healthy, adul t, male or female of non -childbearing potential ( Appendix D), 19- 55years of 
age, inclusive, at screening.
2.Male participants or female of non -childbearing potential agrees to comply  with any 
applicable contraceptive requirements of the protocol as detailed in Appendix D.
3.BMI ≥18.0 and ≤32.0 kg/m2at scre ening. 
4.Continuous non -smoker who has not used nicoti ne-containing products for at least 90 day s 
prior to the first dosing.
5.Medically  healthy wi th no clinically  significant m edical history , physical examinat ion, 
laboratory  profiles, vi tal signs or ECGs, as deemed by the Investigator or designee.
Supine blood pressure is ≥90/40 mmHg and ≤140/90 mmHg at screening;
Supine pulse rate is ≥45 bpm  and ≤100 bpm  at screening;
QTcF i s ≤450 msec (m ales) or ≤470 m sec (females) and ECG findings considered normal 
or not clinically significant by the Invest igator or designee at screening;
Estimated creatinine clearance ≥80 m L/min at screening.
Liver function tests including ALT or AST ≤ 1.5 X the ULN at screening and check -in.
6.Able to swallow mult iple tablets/capsules.
7.Understands the study  procedures i n the ICF, and be willing and able to comply  with the 
protocol .
7.2 Exclusion Criteria
Parti cipants m ust not be enrolled in the study  if they meet any  of the f ollowing cri teria before the 
first dose of study  drug: 
1.Is mentally  orlegally incapacitated or has significant emotional problems at the time of the 
screening visit or expected during the conduct of the study .
2.History  or presence of clinically significant medical or psy chiatri c condi tion or di sease in the 
opinio n of the Inv estigator or designee.
3.History  or presence of gastrit is, GI tract, gastri c bypass surgery , or hepati c disorder or other 
clinical condit ion which, in the opinio n of the Investigator or designee, may  affect the 
absorpti on, di stribut ion, metabolism, or eliminat ion of study  drugs. 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 32of 75
Protocol 23 August 2021
4.History  or presence of any of the fo llowing, deem ed clinically  significant by  the invest igator:
epilepsy , seizure, or convulsio n, tremor or related symptoms; 
arrhy thmias or other cardi ovascular disorder;
GI disorder (eg peptic ulcer disease, gastroesophageal reflux disease, impact ion, chronic 
constipation, inflammatory  bowel  disease, i schemic colit is, vascular intestinal 
atherosclerosis, previous bowel resect ion, bowel obstruction, bariatric surgery , 
cholecyst itis, intestinal ulcerat ion or inflammat ion);
GI bl eeding or perforation;
recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulcerat ion or 
bleeding);
known bleeding or coagulat ion disorders; 
history  of thromboembolic events;
hyperkalemia.
5.History  or prese nce o f cataracts or other clinically  significant visio n disturbances. 
6.History  of any illness that, i n the opinio n of the Investigator or designee, might confound the 
resul ts of the study  or poses an addi tional risk to the parti cipants by  their parti cipat ion in the 
study .
7.History  or presence of alcoho lism or drug abuse within the past 2 years prior to the first dosing.
8.History  or presence of hypersensit ivity or idiosyncrati c reacti on to the study drugs or rel ated 
compounds.
9.Part 2 only: Known or suspected t o be poor CYP2C9 metabo lizers based on previous 
history /experience wit h other CYP2C9 substrates. 
10.Any posi tive responses on the C -SSRS that in the clinical judgement of the Invest igator has a 
risk of suicide or has made a suicide attempt in the previous 12 months pr ior to the first dosing.
11.Female participants of childbearing potential.
12.Female participants with a positive pregnancy test at screening or check -in or who is lactating.
13.Positive urine drug or alcoho l resul ts at screening or check -in.
14.Positive res ults at screening for HIV, HBsAg or HCV.
15.Unable to refrain fro m or anti cipates the use of:
Any drug, including prescription and non -prescri ption medicati ons, herbal  remedies, or 
vitamin supplements within 14 days pri or to the first dosing. Thy roid horm one 
replacement m edicat ion may be permitted if the participant has been on the same stable 
dose for the immediate 3 months prior to first dosing. 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 33of 75
Protocol 23 August 2021
Any drugs known to be significant inducers of CYP3A, CYP2C9 (Part 2), CYP2C19, 
UGT1A9 or UGT2B4 enzymes and/or P gp, including St. John’s Wort, within 28 days 
prior to the first dosing. Appropriate sources (eg, Flockhart TableTM) will  be consul ted to 
confirm lack of PK/pharmacodynamics interaction with study  drug.
16.History  of alcohol  consumpt ion exceeding 2 standard d rinks per day on average (1 glass is 
approximately  equivalent to the following: beer [354 mL/12 oz], wine [118 mL/4 oz], or 
distilled spirits [29.5 mL/1 oz] per day ).
17.Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximatel y 
equivalent to 120 mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated 
beverages per day .
18.Has been on a diet inco mpat ible with the on -study  diet, in the opinio n of the Invest igator or 
designee, within the 30 days pri or to the first dosing and throughout the study.
19.Donati on of  blood or si gnificant blood loss within 56 days prior to the first dosing.
20.Plasma donat ion within 7 days pri or to the first dosing.
21.Parti cipation in another clinical study  within 30 days or 5 half -lives prior to the first dosing. 
The 30 -day window or 5 half -lives will be derived fro m the date of the last blood collect ion or 
dosing, whichever is later, in the previous study  to Day 1 of Period1 of the current study .
7.3 Excluded Medications ,Supplements, Dietary Produc ts
Concomitant medicat ions will be prohibited as listed in the exclusio n criteria in Sect ion 7.2and 
throughout the study , including the fo llow-up period. After the first dose, ibuprofen (up to 1.2 g 
per 24 hour period) may be administered at the discretion of the Invest igator or designe e. Thy roid 
horm one repl acement m edicat ion may be permitted if the participant has been on the same stable 
dose for the immediate 3 months prior to the first dosing.
If deviat ions occur, the Investigator or designee in consultation wit h the Sponsor if neede d will 
decide on a case by  case basis whether the participant may  cont inue participation in the study.
All medications taken by participants during the course of the study  will be recorded.
Use of excluded agents (prescript ion or non -prescript ion) or dieta ry products i s outlined in 
Table 7.a.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 34of 75
Protocol 23 August 2021
Table 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and First Dosing (Days 
-28 to predose [Day 1])After First Dosing (Day 1) to 
Follow -Up 
Alcohol Prohibited from 48 hours prior to first dosing Prohibited from first dosing until 
the end of PK collection.
Xanthine and/or caffeine Prohibited from 24 hours prio r to first dosing aProhibited from first dosing until 
the end of PK collection.a
Medications See Sections 7.1and 7.2 See Sections 7.1and 7.2
Nicotine -and 
tobacco -containing and/or 
cannabis productsProhibited from 90 days prior to first dosing Prohibited from first dosing until 
the follow -up.
Food substance
Grapefruit/Seville orange Prohibited from 14 days prior to first dosing Prohibited from first dosing until 
the end of PK collection.
Other Fruit Juice Prohibited from 12 hours prio r to first dosing Prohibited from first dosing until 
the end of PK collection.
Vegetables from the 
mustard green family 
(eg,kale, broccoli, 
watercress, collard greens, 
kohlrabi, Brussels sprouts, 
mustard), and charbroiled 
meatsProhibited from 7 days prior to first dosing Prohibited from first dosing until 
the end of PK collection.
(a) small amounts of caffeine derived from normal foodstuffs eg, 250mL/8 oz./1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be 
considered a deviation to this restriction.
7.4 Diet, Fluid, Activity 
7.4.1 Diet and Fluid
Water (e xcept water provided wit h each dosing) will be restricted 1 hour prior to and 1 hour after 
each m orning dose, but will be allowed ad libitum at all other times in Period 2 of Part 2, when 
dosing occurs at the CRU. Other fluids may  be given as part of m ealsand snacks but will be 
restri cted at all other times throughout the confinement period.
Part 1: DDI with itraconazole: On Day 1 of Period1 and on Day 5 of Period 2, parti cipants will 
fast overnight for at least 10 hours prior to dosing and will cont inue to fast for at l east 4 hours 
postdose. On all other dosing days in Period 2, participants will fast at least 1 hour before until at 
least 2 hours postdose .
Part 2: DDI with mefenamic acid: On Day 1 of Period 1 participants will fast overnight for at least 
10 hours prior to soticlestat dosing and will continue to fast for at least 4 hours postdose. On the 
first m orning dose of Day 2 of Period 2, participants will fast overnight for at least 6 hours prior to 
mefenamic and soticlestat dosing and will continue to fast for at least 4 hours postdose. For all 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 35of 75
Protocol 23 August 2021
other m efenamic acid dosing in Period 2, parti cipants will  consume a standard m eal or snack 
immediately  prior to dosing, and the parti cipant will fast for at least 2 hours postdose. The last 
mefenamic acid dos e on Day  1 of Period 2 (the 4thdose) should only be taken with a light snack. 
Parti cipants shoul d not lie down for at least 10 minutes after taking mefenamic acid.
When confined, standard meals and snacks will be provided at appropriate times, except when
they are requi red to fast. When confined in the CRU, participants will be required to fast from all 
food and drink except water between meals and snacks.
Each m eal and/or snacks served at the CRU will be standardized and will be similar in caloric 
content and composit ion and will be taken at approximately the same time in each period.
7.4.2 Activity
All participants will remain seated for the first 4 hours following the morning dose of soticlestat, 
except when they  are supine or semi  reclined for study  procedure s. Participants will then resume 
norm al activity.
However, should AEs occur at any  time, parti cipants m ay be pl aced in an appropri ate posi tion or 
will be permitted to lie down on their right side. During the first 4 hours post soticlestat dose, 
participant s may be allowed to rise for brief periods under supervisio n (eg, in order to use the toilet 
facilit ies).
Parti cipants will be instructed to refrain from strenuous phy sical activity which coul d cause 
muscle aches or injury, including contact sports at any time from screening unt il completion of the 
study . 
7.5 Criteria for Discontinuation or Withdrawal of a Participant
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the case report form (CRF) using the fo llowing categori es.
1.Pretreatment event (PTE) or AE: The participant has experienced a PTE or AE that requires 
early  terminat ion because continued participation imposes an unacceptable risk to the 
participant’s healt h or the participant is unwilling to conti nue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies
Study  drug should be discont inued immediately with appropriate clinical fo llow-up (including 
repeat l aboratory  tests, until a participant’s laboratory  profile has retu rned to normal/baseline 
status, see Section 9.2.8 ), if the fo llowing circumstances occur at any  time during study  drug 
treatm ent:
ALT or AST >8x ULN, or
ALT or AST >5x ULN and persists for more than 2 weeks, or
ALT or AST >3x ULN in conjunct ion with elevated total bilirubin >2 x ULN or 
internat ional norm alized rati o (INR) >1.5, or
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 36of 75
Protocol 23 August 2021
ALT or AST >3x ULN with appearance o f fatigue,  nausea, vo miting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%).
QTcF interval: 
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up if a QTcF 
interval  >500 msec or if there is an increase of QTcF >60 msec above screen ing/baseline 
detected by  ECG and confirmed wit h a repeat ECG. Appropriate clinical fo llow-up includes a 
repeat ECG.
2.Significant protocol  deviat ion: The discovery post -enrollment that the participants failed to 
meet protocol entry  criteria or di d not adhere to protocol  requi rements, and continued 
participat ion poses an unacceptable risk to the participant’s healt h.
3.Lost to follow- up: Attem pts to contact the participants were unsuccessful. Attempts to contact 
the participant must be documented in the particip ant’s source documents.
4.Voluntary  withdrawal: The participants (or participant’s legally  acceptable representative) 
wishes to withdraw fro m the study. The reason for withdrawal, if provided, should be recorded 
in the case report form (CRF). 
Note: All atte mpts should be made to determine the underlying reason for the withdrawal 
and, where possible, the primary underlying reason should be recorded (ie, withdrawal due 
to an AE should not be recorded in the “voluntary  withdrawal” category ). If a parti cipant 
chooses to wi thdraw from  study  parti cipat ion due to personal concerns related to the 
COVID -19 pandemic (other than a COVID -19-related AE), this should be specified as the 
reason for participant withdrawal in the CRF. 
5.Study  terminat ion: The Sponsor, IRB/ IEC , or regulatory  agency  terminates the study .
6.Pregnancy: as described in
 Appendix D.
7.Parti cipants may be withdrawn fro m the study by the Invest igator or designee for the following 
reasons:
Difficult ies in blood collect ion. 
Positive urine drug or alcoho l test. 
8.Other. The specific reasons for discontinuation should be entered into the CRF including 
unavo idable circumstances such as the COVID -19 pandemic. Parti cipants m ay be wi thdrawn 
from the study  at any  time at the di scret ion of the Investigator or Sponsor for safet y reasons 
which should be entered into the CRFs.
7.6 Procedures for Discontinuation or Withdrawal of a Participant
The Investigator may  discontinue a participant’s study  parti cipat ion at any  time during the study  
when the participant meets the study  terminat ion criteria described in Sect ion
 7.5. In addit ion, a 
participant m ay discont inue his or her participat ion without giving a reason at any time during the 
study . Shoul d a parti cipant’s parti cipat ion be discont inued, the primary criterio n for termination 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 37 of 75
Protocol 23 August 2021
must be recorded by the Investigator. In addition, efforts should be made to perform all procedures 
scheduled for the end-of-study or early termination as described in Section 3.0.
7.7 Participant Replacement
Replacement of discontinued or withdrawn participants due to any reason will be assessed on a 
case by case basis, by the Sponsor and Investigat or to ensure that 12 PK-evaluable participants 
complete each part of the study.
8.0 CLINICAL STUDY MATERIAL MANAGEMENT
8.1 Clinical Study Drug 
Investigational Medicinal Product(s) (Parts 1 and 2)
Product Name: Soticlestat (TAK-935)
Strength: 
Dose: 300 mg 
Dosage Form/Formulation: 
Dosing regimen: Single dose 
Route of Administration: Oral
Interacting Drug (Part 1) 
Product Name: Itraconazole 
Strength: 10 mg/mL 
Dose: 200 mg (20 mL of 10 mg/mL)
Dosage Form/Formulation: Solution
Dosing regimen: Multiple dose (QD)
Route of Administration: Oral
Preference for generic or brand name: Brand name or generic.
Interacting Drug (Part 2) 
Product Name: Mefenamic acid
Strength: 250 mg 
Dose: 250 mg (1 x 250 mg strength)
(500 mg [2 x 250 mg strength] for the first dose)
Dosage Form/Formulation: CapsuleCCI
CCI
CCIe
Property of Takeda: For Non-Commercial Use Only ngle dongle do
OralO
ulatlatioion: n
ministra t
ce for gce for 
teractinract
ofProduc
StrSd Subject to the Applicable Terms of Usen a 
pantn
))
d Sund Subject to the Applicable Terms of Used ono
ticipci
935)35
nd SI
y and
Pr     Pr    ministrminist
ce for ce for 
teractiract
ProduProdu
SS    ngle dgle d
OralOr       s e       s eon a on a
icipanipan
35)35)
  
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 38of 75
Protocol 23 August 2021
Dosing regimen: Multiple dose (QID)
Route of Administration: Oral
Preference for generic or brand name: Brand name or generic.
8.1.1 Clinical Study Drug Labeling
Study  drug containers will be affixed with a clinical label in acc ordance wi th local regulatory  
requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
The Sponsor will supply sufficient quant ities of soticlestat to allow complet ion of this study . 
Celeri on will supply sufficient quantit ies of itraconazole and mefenamic a cid to allow complet ion 
of this study .
For all study  medicati ons (i e, soti clestat, i traconazol e, and mefenamic acid), the same lot number 
will be used throughout the study . The l ot numbers and expirat ion dates (where available) of the 
study  drugs supplied will be recorded in the final report. Study  drugs will be stored according to 
the product labels provided with the product.
Records will be made of the receipt, preparation, dispensing, and final disposit ion of the study  
drugs supplied.
8.1.3 Clinical Study Drug Blinding
This is an open -label study . 
8.1.4 Randomization Code Creation and Storage 
Not applicable. 
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
Not applicable.
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
Records will be made of the rec eipt and dispensing of the study drugs supplied. At the conclusio n 
of the study , any unused soti clestat will be retained by  Celeri on, returned to the Sponsor or 
designee, or destroy ed, as per Sponsor instructions. Any remaining supplies that were purchased
by Celerio n will be destroyed, if appropriate. If no supplies remain, this fact will be documented in 
the pharmacy  product accountabilit y records.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 39of 75
Protocol 23 August 2021
9.0 STUDY PROCEDURES
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
The purpose of the study , the procedures to be carried out and the potential hazards will be 
described to the participants in non -technical terms. Participants will be required to read, sign, and 
date an ICF summarizing the discussio n prior to screening, and will be assured that they  may 
withdraw from  the study  at any  time wi thout jeopardi zing thei r medical  care.
Parti cipants will be given a copy  of their signed ICF.
9.1.1.1 Assignment of Screening Numbers 
Each participant will be assigned a unique ident ification number upon screening. Partici pants who 
complete the study  screening assessments and meet all the eligibilit y criteria will be assigned a 
unique identificat ion number at the time of first dosing in Period 1, different fro m the screening 
number.
If replacement participants are used, the replacement participant number will be 100 more than the 
original  parti cipant’s i dentificat ion number (eg, Participant No. 101 will assigned to the 
replacement of Participant No. 1).
9.1.1.2 Study Drug Assignment
All participants will receive the treatments as de tailed in Sect ion 9.2.6 . 
9.1.2 Inclusion and Exclusion 
Please refer to Section 7.1and Section 7.2.
9.1.3 Medical History/ Demography
Medical history  and dem ographic data, including name, sex, age, race, ethnicit y, and history  of 
tobacco use will be recorded.
9.1.4 Concomitant Medications
Concomitant medicat ions will be prohibited as listed in Section 7.3. All medica tions taken by 
participants during the course of the study  will be recorded.
9.2 Clinical Procedures and Assessments
The Schedule o f Study  Procedures (Secti on3.0) summarizes the clinical procedures to be 
perform ed at each visit. Individual clinical procedures are described in detail below. Addit ional 
evaluat ions/testing may be deemed necessary  by the invest igator or designee and/or the Sponsor 
for reasons related to parti cipant safet y.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 40 of 75
Protocol 23 August 2021
For this study, collection of blood for soticlestat  is the 
critical parameter and needs to be collected as close to the exact time point as possible. All other 
procedures should be completed as close to the prescribed/scheduled time as possible, but can be 
performed prior to or after the prescribed/scheduled time.
Any nonscheduled procedures required for urgent evaluation of safety concerns take precedence 
over all routine scheduled procedures.
9.2.1 Physic al Exam
A full and abbreviated physical examination will be performed as outlined in the Schedule of 
Study Procedures (Section 3.0).
An abbreviated physical examination will include at the minimum, examination of respiratory, 
cardiovascular, and gastrointestinal systems, with the option for further examination of additional 
systems as necessary based on reported symptoms/AEs.
Symptom-driven physical examinations may be performed at other times, if deemed necessary by 
the Investigator or designee.
9.2.2 Height and Weight
Body height (cm) and weight (kg) will be reported as outlined in the Schedule of Study Procedures 
(Section 3.0).
9.2.3 BMI
BMI will be calculated based on the height and weight measured at screening.
9.2.4 Vital Signs
Single measurements of temperature, respiratory r ate, blood pressure and pulse rate, will be 
measured as outlined in the Schedule of Study Procedures (Section 2.0). Additional vital signs 
may be taken at any other times, if deemed necessary.
Blood pressure and pulse rate measurements will be performed with participants in a supine 
position (5 minutes).
Vital signs will be measured within 24 hours pri or to Day 1 dosing of Period 1 for the predose time 
point. At all other predose time points, vital signs will be measured within 2 hours prior to dosing. 
When scheduled postdose, vital signs will be performed within approximately 15 minutes of the 
scheduled time point. 
9.2.5 12-Lead ECG
Single 12-lead ECGs will be performed as ou tlined in the Schedule of Study Procedures 
(Section 3.0). Additional ECGs may be taken at any other times, if deemed necessary by the 
Investigator or designee.CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee 
cedence cede
n the Schthe 
xaminatamina i
rther exther
at other othe
ted ted as ouo
he heighheigh
emperamper
n the Scn the S
yother tothery
and puland pu
minutes) te
ns will bns will
 At all oAt all
hen scheen sc
scheduld
9.9
Pr    Pr    and puand pu
minutesinute
ns willns will
At allAt all
hen schen sc
schedusched
99          s e         s eedencdenc
the Scthe S
aminamina
ther eher e
t otheothe
ed d as oas o
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 41of 75
Protocol 23 August 2021
ECGs w ill be perform ed wi th parti cipants in a supine posit ion (5 minutes). All ECG tracings will 
be reviewed by the Invest igator or designee.
ECGs will be measured within 24 hours prior to Day 1 dosing of Peri od 1 f or the predose time 
point. At all other predose time points, ECGs will be measured wit hin 2 hours prior to dosing. 
When scheduled postdose, ECGs will be performed within approximately 20 minutes of the 
scheduled time po int.
9.2.6 Study Drug Administration
Study  drugs and study  drug form ulationswill be provi ded as described in Sect ion 8.1.
Dose regimens for study  drugs are described in Table 2.band  Table 2.d.
After init ial morning dosing of mefenamic acid on Day  1 of Period 2, each subse quent first daily 
dose will be administered within ± 1 hour of dosing time established on Day  1 of Period 2. Each 
subsequent dose on the same day will be approximately 6 hours after the morning dose on that day.
The pharmacy at the CRU will provide each do se in individual unit dose containers for each 
participant, as appropriate. 
Study  drugs will be administered with approximately 240 mL o f water.
Addit ional information regarding drug preparation and administration may be provided in a 
separate document. 
Parti cipants will be instructed not to crush, split, or chew the tablets/capsules.
The exact clock time of dosing will be recorded.
A qualified designee will be responsible for monitoring the administration of the assigned doses. A 
mouth check will be perf ormed by  the qualified desi gnee to ensure that the participants have 
swallowed the study  drug(s). Once a participant has finished the dosing water, the qualified 
designee will use a flashlight and a tongue depressor to check the participant’s mouth. 
Parti cipants’ hands will also be verified to ensure that the study  drug(s) was ingested.
9.2.7 C
-SSRS
Suicidal  ideati on will  be assessed using the C -SSRS at the times stipulated in the Schedule of 
Study  Procedures for each study  part (Secti on 3.0). Two versions of the C -SSRS will be used in 
this study : the Screening/Baseline C -SSRS Lifet ime and the Since -Last-Visit C -SSRS. It i s 
recommended that the same rater be used to administer the scale to the participant at all t imepoints 
when C -SSRS i s scheduled. Any  suicidal  ideati on or suicidal  behavi or during the tri al periods 
detected by  the C -SSRS will be recorded as an AE. The invest igator will ensure that any suicidal
ideat ion or behavior is medically addressed, including assessment and treatment by  qualified 
medical personnel.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 42of 75
Protocol 23 August 2021
9.2.8 AE Monitoring
Parti cipants will be monitored throughout the study for adverse reactions to the study drugs and/or 
procedures as described in Section 10.0.
9.2.9 Laborator y Procedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study  Procedures 
(Secti on3.0). In addit ion, laboratory  safet y tests may  be performed at various unscheduled time 
points, if deemed necessary  by the Invest igator or designee.
9.2.9.1 Clinical Laboratory Tests
Hematology
Hem atology will consist of the following tests:
Hemoglobin Red blood cell count
Hematocrit Platelet count
Erythrocy tes Mean platelet volume
Total and differential leukocyte count Immune cell count (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils)
Coagulation
Coagulation test will be conducted as outlined in the Schedule of Study  Procedures (Secti on2.0).
Coagulation test will consist of the fo llowing tests:
Activated partial thromboplastin time (aPPT)
Prothrombin time (PT)/ INR
Chemistry 
Serum  chemistry  tests will be performed after at least an 8 -hour fast; however, in case o f dropouts 
or rechecks, p articipants may not have fasted for 8 hours prior to when the serum chemistry sample 
is taken.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 43of 75
Protocol 23 August 2021
Chemistry  evaluat ions will consist of the following standard chemistry  panel:
Blood Urea Nitrogen Albumin
Bilirubin (total, direct and indirect) Sodium
Alkaline phosphatase (ALP) Potassium
Aspartate aminotransferase (AST) Chloride
Alanine aminotransferase (ALT) Glucose
Calcium Creatinine **
Carbon dioxide Phosphate
Protein (total) Alpha1 -acidic glycoprotein (AGP) (screening only)
Gamma -glutamyl transferase (GGT) Magnesium
Urea
** At screening, creatinine clearance will be calculated using the Cockcroft -Gault formula.
Urinalysis
Urinalysis will consist of the fo llowing tests:
pH Bilirubin
Specific gravity BloodBlood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
Erythrocy tes Creatinine
Calcium
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epithelial cells) will be performed.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 44 of 75
Protocol 23 August 2021
9.2.9.1.1 Other 
HIV test Urine drug screen
Opiates (includes morphine, heroin (diacetylmorphine), 
codeine, 6-acetylmorphine, dihydrocodeine, hydrocodone, thebaine, and, hydromorphone)
AmphetaminesBarbiturates
Benzodiazepines
Cocaine
Cannabinoids
Buprenorphine/metaboliteMDMA (3,4-methylenedioxy-methamphetamine)
Methadone/metabolite
Oxycodone/oxymorphone
PhencyclidineHBsAg
HCV (if antibody positive, confirm RNA negative)
Urine alcohol screen
Serum pregnancy test (for females only)
FSH (for females only)
COVID-19 (SARS-CoV-2 polymerase chain reaction 
test or equivalent)
9.3 Pharmacokinetic Samples
Samples for assessment of soticlestat will be collected 
as delineated in Table 9.a.
Instructions for sample collection, processing, and shipping will be provided in separate 
documents. 
Primary specimen collection par ameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample for soticlestat Blood Plasma Plasma sample for PK analysis Mandatory
9.3.1 Pharmacokinetic Measurements 
Samples from all participants will be assayed even if the participants do not complete the study. 
Samples for determination of plasma soticlestat , will be 
analyzed using validated  bioanaly tical met hods.
Pharmacokinetic parameters of soticlestat  will be 
calculated from the individual concentration-time profiles from all evaluable participants using 
noncompartmental analysis methods . Actual sampling times, rather than scheduled sampling 
times, will be used in all computations involving sampling times. CCI
CCI
CCICCIe
Property of Takedd
Sam
rty of Takeda: For Non-Commercial Use Onssing, asing,
ameters meter
pecimenpecimeCCC
soticlestsoticleor 
a
P
plesply and Subject to the Applicable Terms of Usemeth
nene
ly and Subject to the Applicable Terms of Useone, e, 
xyy
rphoho
S
amam
anaOnly 
a:
Pr    Pr    soticlesoticle 
Samampleplmmm
SamSam
aa   
sing, sing,       s e       s ene, e, 
xyy--yyymetmet
phonehone
 
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 45 of 75
Protocol 23 August 2021
9.3.1.1 Plasma for PK Measurements
The following PK parameters will be calculated from plasma concentrations of soticlestat
, unless otherwise specified:
AUC last: The area under the concentration-time curve, from time 0 to the last 
quantifiable concentration, as calculated  by the linear-log trapezoidal 
method.
AUC∀: The area under the concentration-time curve, from time 0 extrapolated to 
infinity. AUC ∀is calculated as AUC last plus the ratio of the last measurable 
blood concentration to the elimination rate constant.
AUC extrap%: Percent of AUC ∀extrapolated, represented as (1 - AUC last/AUC∀)*100.
Cmax: Maximum observed concentration.
tmax: Time to reach C max. If the maximum value occ urs at more than one time 
point, t maxis defined as the first time point with this value.
No value for AUC ∀, AUC extrap%, ill be re ported for cases that do not 
exhibit a terminal log-linear phase in the concentration versus time profile.
No PK parameters will be calculated for participants with detectable concentrations at 2 or fewer 
consecutive time points. 
Individual and mean plasma concentration-curves (both linear and log-linear) will be included in 
the final report.
Additional PK parameters may be estimated as appropriate.
9.3.2 Biomarker Mea surements 
Not applicable.CCI
CCICCI
CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useidalidal
extrapolxtrap
the lasthe las
--AUCAU
ummval
st time ptime
AUCU∀A
rminal lmina
parameparam
ecuteciveiv
Individv
he fe
Abject to t
or Non-Commercial Use Only a
Pr     Pr    AUCUC∀
rminalmina
paramparam
ecutecutiviv
IndiviIndivi
ththee  mm va vam
t timetime    se    sedal dal 
xtrapoxtrapo
he lashe las
AUCAU
    
     
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 46of 75
Protocol 23 August 2021
9.3.3 PGx Measurements 
Not applicable.
9.3.4 Confinement
Parti cipants will  be housed on Day -1 of Period 1, at the time indicated by the CRU, until after the 
last bl ood draw and/or study  procedures on Day  12 of  Period 2 f or Part 1 or un til after the last 
blood draw and/or study  procedures on Day 8 of Period 2 for Part 2. Participants may be asked to 
check -in to the CRU earlier to undergo addit ional COVID- 19 precaution procedures or testing not 
related to study  protocol , as per CRU requi rements.
Atall times, a participants may be required to remain at the CRU for longer at the discret ion of the 
Invest igator or designee. 
The CRU will contact all part icipants (including participants who terminate the study  early) 
15(±2) day s after the last soticles tat administrati on by tel ephone or other methods per CRU 
standards to determine if any AEs have occurred and/or any  concomi tant m edicati ons have been 
taken since the last study  visit. If clinically significant findings are observed upon discharge, 
participants m ay return to the CRU for re -evaluat ion per Invest igator’s discretion.
10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation parti cipants who  
has signed informed consent to participate in a study; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underly ing disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 47of 75
Protocol 23 August 2021
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e action or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repe ated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, in creased creatinine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  procedure. However, if the participant experiences a worsening or 
complicat ion of such a concurrent medical history  condi tion, the worsening or complication 
shoul d be recorded appropriately as an AE (worsening or complicat ion occurs after informed 
consent is signed). Investigators should ensure that the event term recorded captures the 
change in the cond ition (eg, “worsening of…”).
If a participant has a pre -exist ing episodic condit ion (eg, asthma, epilepsy ), any occurrence of 
an episode should only be captured as an AE if the episodes beco me more frequent, serious, or 
severe in nature, that is, invest igators shoul d ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a participant has a degenerat ive concurrent condit ion (eg, cataracts, rheumatoid arthrit is), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the participant experiences a worsening or complicat ion of an AE after the first 
administration of study  medicati on or after any  change in study  medicat ion, the worsening or 
complicat ion shoul d be recorded as a new AE. Investigators should ensure that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Changes in severit y of AEs:
If the participant experiences a change in the severit y of an AE that i s not associ ated wi th a 
change in study  medicati on, the event shoul d be captured once with the maximum severit y 
recorded.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 48of 75
Protocol 23 August 2021
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures perfor med where there is no change in the participant’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the participant’s source 
docum ents. Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overd ose is defined as a known deliberate or accidental administration of investigational 
drug, to or by  a study parti cipant, at a dose above that which is assigned to that individual 
participant according to the study  protocol . It is up to the invest igator or the reporting 
physician to decide whether a dose is to be considered an overdose, in consultat ion with the 
Sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the electronic CRF, in order to capture this important safet y info rmation consistently in 
the database. AEs associated with an overdose will be documented on AE CRF(s) according to 
Secti on10.0.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Sect ion 10.2.8 .
In the event of drug overdos e, the participant should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the participant was at risk of death at 
the time o f the event; it does not refer to an event that hypothetically  might have caused 
death if it were more severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4.Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 49of 75
Protocol 23 August 2021
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the parti cipant to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Table 10.a Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal productToxic epidermal necrolysis/
Stevens -Johnson syndrome
COVID -19 pneumoniaNeuroleptic malignant syndrome / malignant hyperthermia
COVID -19-related disease Spontaneous abortion / stillbirth and fetal death
Abbreviations: COVID -19 = Coronavirus disease -2019
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and fo llowed up in the same manner (see Sections 10.1 and 10.1.1 ).
10.1.2 Special Interest AEs
There are no AEs of Special Interest for this study .
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of A Es
The different categories o f severit y/intensity are:
Mild: An adverse event that is usually transient and may require only  minimal 
treatm ent or therapeutic intervent ion. The event does not generally interfere 
with usual  activi ties of  daily living.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 50of 75
Protocol 23 August 2021
Moder ate: An adverse event that is usually alleviated with addit ional specific therapeut ic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participan t.
Severe: An adverse event that interrupts usual activit ies of daily living, or significant ly 
affects clinical status, or may require intensive therapeutic intervention.
10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Related: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including the course after withdrawal o f the drug), or for whi ch a causal  
relationship is at least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out , although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not fo llow a reasonable tempo ral sequence from administration 
of a drug and/or that can reasonably be explained by  other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
In addit ion, relat ionship (causalit y) to COVID -19 should be determined for all PTEs and AEs. The 
relationship should be assessed as related if the investigator considers that there is reasonable 
possibilit y that an event is due to COVID -19. Otherwise, the relat ionship should be assessed as not 
related.
Similarly, relationship (causalit y) to COVID -19 vaccines should be determined for all PTEs and 
AEs. The relat ionship should be assessed as related if the investigator considers that there is 
reasonable possibilit y that an event i s due to COVID -19 vaccines. Otherwise, the relationship 
shoul d be assessed as not related. If the AE has relationship to vaccinat ion, specific verbat im term 
shoul d be used, eg, post- vaccinat ion fever, vaccinati on si te burning.
In addit ion, if the causalit y assessment done by the investigator determines that the event or events 
(PTEs or AEs) are related or possible related to COVID -19 or the COVID -19 vaccine, the events 
shoul d be assessed as not related to the invest igational product. If the AE is related to COVID -19 
vaccination, specific verba tim term (s) shoul d be used, eg, post -vaccinat ion fever, vaccinat ion site 
burning.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the parti cipant 
and/or invest igator.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 51of 75
Protocol 23 August 2021
10.2.4 End Date 
The end date of the AE is the date at which the participant recovered, the event resolved but with 
sequelae or the participant died.
10.2.5 Pattern of Adverse Event (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All oth er events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  medicat ion.
Unknown –only to be used if it has not b een possible to determine what action has been taken.
Not applicable –a study  medicat ion was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the participant died, dosing wit h study  medicat ion had not 
yet started or dos ing with study medicat ion was already  stopped before the onset of the AE.
Drug interrupted –the dose was interrupted due to the particular AE.
10.2.7 Outcome 
Recovered/reso lved –participants returned to first assessment status with respect to the AE.
Recoverin g/resolving – the intensit y is lowered by  one or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the participants died fro ma cause 
other than the particular AE with the condit ion remaining “recovering/reso lving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast d ay of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
participant di ed fro m another cause with the part icular AE state remaining “Not recovered/not 
resolved.”
Recovered/ Reso lved wit h sequelae – the participant recovered from an acute AE but was left 
with perm anent/si gnificant impairment (eg, recovered fro m a cardiovascular accident but with 
some persisting paresis).
Fatal  –an AE that is considered as the cause of death.
Unknown –the course of th e AE cannot be fo llowed up due to hospi tal change or residence 
change at the end of the participant’s part icipation in the study .
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 52of 75
Protocol 23 August 2021
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.8.1 Collection Period
Collect ion of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal LFTs) will co mmence at 
the time the participant signs the informed consent. Routine co llection of AEs will continue unt il 
the follow-up contact on 15 (±2) days after last dose of soticles tat. For parti cipants who 
discontinue prior to the administration of study  medication, AEs will be fo llowed unt il the 
participant discont inues study participat ion. 
10.2.8.2 Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Parti cipants may  report AEs occurring at any  other time during the study . Parti cipants 
experiencing an SAE prior to the first exposure to investigat ional product m ust be monitored unt il 
the symptom s subsi de and any  clinically relevant changes in laboratory  values have returned to 
Baseline or there is a satisfactory  explanat ion for the change. Nonserious AEs that begin prior to 
the first exposure to in vestigational product, related or unrelated to the study  procedure, need not 
be followed-up for the purposes of the protocol.
All participants experiencing AEs, whether considered associated with the use of the study  
medicat ion or not, m ust be m onitored un til the symptoms subside and any clinically relevant 
changes in laboratory  values have returned to Baseline or un til there is a satisfactory  explanat ion 
for the changes observed. All AEs will be documented in the AE page of the CRF, whether or not 
the inve stigator concludes that the event is related to the drug treatment. The fo llowing 
inform ation will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/Intensi ty.
Causalit y (Invest igator’s opinio n of th e causal relati onship between the event and 
administration of study  drug[s]).
Relationship to COVID -19.
Relationship to COVID -19 vaccine.
Action taken with study  drug.
Outcom e of event.
Seriousness.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 53of 75
Protocol 23 August 2021
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collecti on peri od it shoul d be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in English and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be completed as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Parti cipant i dentificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment .
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 14.1.1 .
Any SAE spontaneously reported to th e invest igator fo llowing the AE collect ion period should be 
reported to the Sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs oc curring on treatment.
10.2.8.3.1 SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately within 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcom e of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.8.4 Reporting Special Interest AEs 
There are no AEs of Special Interest for soticlestat
10.2.8.5 Reporting of Abnormal LFTs
If a participant is noted to have ALT or AST elevated >3 ×ULN on 2 consecutive occasions, the 
abnorm ality should be recorded as an AE. In addition, an LFT Increases CRF must be completed 
provi ding addit ional information on relevant recent history , risk factors, clinical signs and 
symptoms and results of any addit ional diagnosti c tests performed.
If a participant is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 54of 75
Protocol 23 August 2021
as per Secti on 10.2.8.3 . The i nvest igator must contact the Medical Monitor for discussio n of the 
relevant parti cipant details and possible altern ative etiologies, such as acute viral hepatit is A or B 
or other acute liver disease. Follow -up laboratory  tests as described in Sect ion 9.2.8 must also be 
perform ed. In addit ion, an LFT Increases CRF must be completed and transmitted with the Takeda 
SAE form (as per Section 10.2.9 ). 
10.2.9 Safety Reporting to Investig ators, Institutional Review Board (IRB)s or 
Independent Ethics Committee (IEC)s, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulato ry authori ties, invest igators and IRBs or 
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the Sponsor or 
Sponsor’s designee, SUSARs will be submitted within 7 day s for fatal and life -threatening events 
and 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
Sponsor will also prepare an expedited report for other safety issues where these mig ht materially 
alter the current benefit -risk assessment of an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal products administration or in the 
overall conduct of the study . The invest igational site al so will forward a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h national regulat ions.
11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
Detailed methodology  for summary  and stati stical analyses o f the data collected in this study  will 
be docum ented in a stati stical analysis plan (SAP). This document may modify the plans outlined 
in the protocol; however, any major modifications of the primary endpo ints definit ion and/or its 
analysis will also be reflected in a protocol  amendment. Addi tional stati stical analyses other than 
those described in this sect ion may be perform ed if deem ed appropri ate.
11.1.1 Analysis Sets
11.1.1.1 PK Set
All part icipants who comply sufficient ly with the protocol and display an evaluable PK profile (e g, 
exposure to treatm ent, availabilit y of measurements and absence o f major protocol vio lations) will 
be included in the PK analysis set . More details will be provided in SAP.
11.1.1.2 Safety Set
All participants who received at least one dose of the study  drug(s) will be included in the safet y 
analysis set. More details will be provided in SAP.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 56of 75
Protocol 23 August 2021
11.1.5.1 AEs
AEs will be coded using the most current version of Medical Dict ionary for Regulatory  Activit ies 
(MedDRA®) available at Celerio n and summarized by treatment days (Part 1 soticlesta t alone 
[Peri od 1 Day 1 –Period 1 Day 5 predose]; itraconazole alo ne [Period 2 Day 1 postdose –Period 2 
Day 5 predose]; soti clestat + i traconazol e [Peri od 2 Day  5 postdose to end of study ]; Part 2: 
soticlestat alone [Period 1 Day 1 –Period 1 Day 5 predo se]; mefenamic acid alo ne [Period 2 Day 1 
postdose – Period 2 Day  2 predose]; soticlestat + mefenamic acid [Period 2 Day 2 postdose to end 
of study ]) for the number of participants reporting the TEAE and the number of TEAEs reported. 
A by-participant AE da ta listing including verbat im term, coded term, treatment, severit y, and 
relationship to treatment will be provided.
11.1.5.2 Clinical Laboratory Evaluation
Clinical laboratory  resul ts will be summarized by baseline and treatm ent days (Part 1 soticlestat 
alone [Peri od 1 Day  1 –Period 1 Day  5 predose]; itraconazole alo ne [Peri od2 Day 1 postdose –
Period 2 Day  5 predose]; soti clestat + itraconazole [Period 2 Day  5 postdose to end of study ]; 
Part 2: soticlestat alone [Period 1 Day 1 –Period 1 Day  5 predose]; mef enamic acid alo ne 
[Peri od2 Day 1 postdose –Period 2 Day 2 predose]; soticlestat + mefenamic acid [Period 2 Day 2 
postdose to end of study ]). Point of time o f collect ion and a shift table describing out of normal 
range shifts will be provided.
11.1.5.3 Vital Signs
Vital signs assessments will be summarized by baseline and treatm ent day s (Part 1 soti clestat 
alone [Peri od 1 Day  1 –Period 1 Day  5 predose]; itraconazole alo ne [Peri od2 Day 1 postdose –
Period 2 Day  5 predose]; soti clestat + itraconazole [Period 2 Day  5 postdose to end of study ]; 
Part 2: soticlestat alone [Period 1 Day 1 –Period 1 Day  5 predose]; mefenamic acid alo ne 
[Peri od2 Day 1 postdose –Period 2 Day 2 predose]; soticlestat + mefenamic acid [Period 2 Day 2 
postdose to end of study ]) point of time of collect ion.
11.1.5.4 Other Safety Parameters
Physical examinat ion findings will be presented in the data list ings.
ECGs baseline and treatment days (Part 1 soticlestat alone [Period 1 Day  1 –Period 1 Day  5 
predose]; itraconazo le alone [Period 2 Day 1 postdose –Period 2 Day  5 predose]; soti clestat + 
itraconazo le [Period 2 Day 5 postdose to end of study]; Part 2: soticlestat alone [Period 1 Day 1 –
Period 1 Day  5 predose]; mefenamic acid alo ne [Peri od2 Day 1 postdose –Period 2 Day  2 
predose]; soticlestat + mef enamic acid [Period 2 Day 2 postdose to end of study]) and point of time 
of collect ion.
C-SSRS results will be summarized by point of time of co llection.
Medical history , and concurrent condit ions will be coded using the MedDRA®and conco mitant 
medicat ions will be coded using the World Healt h Organizat ion (WHO) drug dict ionary and will 
be listed by part icipant.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 57 of 75
Protocol 23 August 2021
11.2 Interim Analysis and Criteria for Early Termination
Not applicable.
11.3 Determination of Sample Size
12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study-Site Monitoring Visits
Monitoring visits to the study site will be mad e periodically during the study to ensure that all 
aspects of the protocol are followed. Due to COVID-19, monitoring visits may also be conducted 
remotely. Source documents will be reviewed  for verification of data recorded on the CRFs. 
Source documents are defined as original documents, data, and records. The investigator and study 
site guarantee access to source documents by the Sponsor or its designee (CRO) and by the IRB or 
IEC.
All aspects of the study and its documentation w ill be subject to review by the Sponsor or the 
Sponsor’s designee (as long as blinding is not jeopardized), including but not limited to the 
Investigator’s Binder, st udy drug, participant medical records, informed consent documen tation, 
and review of CRFs and associated source documents. It is important that the investigator and CCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTY CONTY CO
udu SitS
ring vising v
cts of thcts of t
motelye
Sourceurc
siiteii
INon-Commercial Use Only and Subject to the Applicable Term
Pr    Pr    TY CTY C
udyudy--SiS
ring viing v
cts of tcts of t
mmotelyote
SourcSourc
sisiti  se  se
               
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 58of 75
Protocol 23 August 2021
other study  personnel are available during the mo nitoring visits and that sufficient time is devoted 
to the process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study  parti cipants. Shoul d other unexpected ci rcumstances arise that will 
requi re deviat ion from protocol -specified procedures, the invest igator should consult with the 
sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of act ion. 
There will be no exempt ions (a prospectively approved deviat ion) from the inclusion or exclusio n 
criteria.
For COVID -19-related protocol deviat ions, the specific protocol deviation, the reason for the 
deviat ion, and the relat ionship to COVID -19 should be documented using CRU standard 
processes.
Significant d eviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the health risk to the participant, or confound interpretation of primary study assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also may  be subject to qualit y assurance audi ts by  the Sponsor or designees. In this 
circumstance, the Sponsor -designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory samples are co llected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, th e FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the Sponsor should be notified 
immediately . The investigator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion
 12.1.
13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, 
participants) accordi ng to the protocol, the ethical principles that have their origin in the 
Declaration of Helsinki, and the Internat ional Conference on Harmonizat ion(ICH) Harm onized 
Tripartite Guideline for GCP. Each invest igator will conduct the study according to applicable 
local or regi onal regulatory  requi rements and align his or her conduct in accordance with the 
“Responsibilit ies of the Investigator” that are l isted in Appendix A. The principles of Helsinki are 
addressed through the protocol and through appendices containing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing region. The Sponsor or designee will require documentation noting all names 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 59of 75
Protocol 23 August 2021
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those Americas sites unwilling to p rovide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The Sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the ICF, and, if applicable, participant recruit ment materi als and/or advertisements and other 
documents required by all applicable laws and regulat ions, m ust be submitted to a central or local 
IRB or IEC for approval. The IRB’s or IEC’s written approval o f the protocol  and parti cipant 
inform ed consent m ust be obtained and submitted to the Sponsor or d esignee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, ICF) reviewed; and state the 
approval  date. The Sponsor will ship drug/notify sit e once the Sponsor has confirmed the adequacy 
of site regulatory  docum entati on and, when applicable, the Sponsor has received permissio n from 
competent authori ty to begin the study . Until the site receives drug/notificat ion no protocol 
activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regardi ng protocol  amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  parti cipants, l ocal safet y reporting requirements, reports and 
updates regarding the ongoing review of the study  at intervals specified by the respect ive IRB or 
IEC, and submissio n of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the Sponsor or its 
designee.
Parti cipant incent ives should not exert undue influence for partic ipation. Payments to participants 
must be approved by the IRB or IEC and Sponsor.
13.2 Participant Information, Informed Consent, and Participant Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaratio n of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, participant authorizat ion form (if applicable), and 
participant informat ion sheet (if applicable) describe the planned and permitted u ses, transfers, and 
disclosures of the parti cipant’s personal and personal healt h informat ion for purposes of 
conducting the study. The ICF and the participant informat ion sheet (if applicable) further explain 
the nature of the study, its object ives, and p otential  risks and benefits, as well as the date informed 
consent is given. The ICF will detail the requirements of the participant and the fact that he or she 
is free to withdraw at any  time without giving a reason and wit hout prejudice to his or her furt her 
medical care.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 60of 75
Protocol 23 August 2021
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the participant authorizat ion form. The ICF, parti cipant authori zation form (if 
applicable), and participant informat ion sheet (if applicable) must be approved by both the IRB or 
IEC and the Sponsor prior to use.
The ICF, participant authorizat ion form (if applicable), and participant informat ion sheet (if 
applicable) must be written in a language fully comprehensible to the prospective participant. It is 
the responsibilit y of the invest igator to explain the detailed elements of the ICF, participant 
authori zation form (if applicable), and participant informat ion sheet (if applicable) to the 
participant. Inform ation should be given in both oral and written form whenever possible and in 
the manner deemed appropriate by the IRB or IEC. In the event the participant is not capable of 
rendering adequate written informed consent, then the participant’s legally acceptable 
representati ve may provide such consent for the participant in accordance with applicable laws and 
regul ations.
The parti cipant, or the participant’s legally acceptable representative, must be given ample 
opportunit y to: (1) inquire about details o f the study, and (2) decide whether or not to participate in 
the study. If the participant, or the participant’s legally acceptable representative, determines he or 
she will participate in the study , then the ICF and participant authorizat ion form (if applicable) 
must be sign ed and dated by  the parti cipant, or the participant’s legally acceptable representative, 
at the time of consent and prior to the participant entering into the study . The parti cipant or the 
participant’s legally acceptable representative should be instructe d to sign using their legal names, 
not ni cknames, using blue or black ballpo int ink. The investigator must also sign and date the ICF 
and part icipant authorizat ion (if applicable) at the time of consent and prior to participant entering 
into the study; how ever, the Sponsor may allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original ICF, participant authorization form (if applicable), and participant 
inform ation sheet (if applicable) will be stored in the invest igator’s site file. The invest igator must 
docum ent the date the participant signs the informed consent in the participant’s medical record. 
Copi es of the signed ICF, the signed participant authorizat ion form (if applicable), and participant 
information sheet (if applicable) shall be given to the participant.
All revised ICFs must be reviewed and signed by relevant participants or the relevant participant’s 
legally acceptable representative in the same manner as the original  informed consent. The date the 
revised consent was obtained should be recorded in the participant’s medical record, and the 
participant shoul d receive a copy  of the revised ICF.
13.3 Participant Confidentiality
The Sponsor and designees affirm and upho ld the principle of the partici pant’s ri ght to protection 
against invasio n of privacy. Throughout this study , a parti cipant’s source data will only be linked 
to the Sponsor’s clinical study  database or docum entati on via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited participant attributes, such as sex, age, or 
date of birth, and participant init ials may be used to verify the part icipant and accuracy  of the 
participant’s unique ident ification number.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 61of 75
Protocol 23 August 2021
To comply wit h ICH Guidelines for GCP and to verify co mpliance with this protocol, the Sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the participant’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a participant’s study  
participat ion, and autopsy  reports. Access to a participant’s original medical records requires the 
specific authorizat ion ofthe participant as part of the informed consent process (see Section 13.2).
Copi es of  any parti cipant source documents that are provided to the Spon sor must have certain 
personally ident ifiable informat ion rem oved (ie, parti cipant nam e, address, and other ident ifier 
fields not collected on the participant’s CRF).
13.4 Publication, Disclosure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The invest igator is obliged to provide the Sponsor with complete test results and all data derived 
by the investigator from the study . During and after the study , only  the Sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than stu dy recrui tment m aterials and/or advertisements, is the sole responsibilit y of the Sponsor.
The Sponsor may publish any data and information fro m the study (including data and informat ion 
generated by  the invest igator) without the consent of the invest igato r. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Study Registration 
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical tri als it Sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wi th invest igator’s cit y, state (for America’s invest igators), country , 
and recruit ing status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing trial 
inform ation. Once part icipants receive invest igator contact information, they may call the site 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 62of 75
Protocol 23 August 2021
inquiries according to their established participant screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they shoul d be referred to the Sponsor.
Any investigator who objects to the Sponsor providing this informat ion to callers must provide the 
Sponsor with a written notice requesting that their informat ion not be listed on the registry  site.
13.4.3 Clinical Study Re sults Disclosure 
Takeda will post the results of clinical studies on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each participan t in the study  must be insured in accordance with the regulat ions applicable to the 
site where the parti cipant is parti cipat ing. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will obtain clinical study  insurance against the ris k of injury  to study 
participants. Refer to the study  site agreement regarding the Sponsor’s policy on participant 
compensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact the Sponsor or Spons or’s desi gnee.
14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contact Information 
Contact Type / Role Contact
Serious adverse event and pregnancy reporting Pharmacovigilance
Takeda Development Center Americas, Inc.
E-mail: PVSafetyAmericas@tpna.com
Fax: +1 (202) 315 -3560
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 63of 75
Protocol 23 August 2021
14.1.2 INVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any other product informat ion provi ded by  the Sponsor. I agree to con duct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  parti cipants in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonizat ion, E6 [R2] Good Clinical Practice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serio us adverse events defined in Sect ion10.2.9 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix A).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 64 of 75
Protocol 23 August 2021
14.1.3 Study-Related Responsibilities 
The Sponsor will perform all study-related activities with  the exception of those identified in the 
Study-Related Responsibilities template. The vendors identified for specific study-related
activities will perform  these activities in full or in partnership with the Sponsor.
14.1.4 List of Abbreviations
ADME Absorption, distribution, metabolism and elimination 
AE Adverse event
ALT Alanine aminotransferase
AST Aspartate aminotransferase
AUC Area under the concentration-time curve
AUC∞ Area under the concentration-time curve from time 0 to infinity
AUC last Area under the concentration-time curve from time 0 to the time of the last quantifiable 
concentration
AUC extrap% Area under the curve from the last quantifiable concentration to infinit y
BID Twice dailyBMI Body mass index
bpm Beats per minuteC-SSRS Columbia-Suicide Severity Rating Scale
CDD CDKL5 deficiency disorder
COVID-19 Coronavirus 2019
CFR Code of Federal Regulations
CH24H Cholesterol 24 S hydroxylase
CI Confidence interval
C
max Maximum observed concentration 
CRF Case report form
CRPS Complex regional pain syndrome
CRU Clinical Research Unit
CSR Clinical study reportCV Coefficient of variance
CYP Cytochrome P450
DDI Drug-drug interaction
DEE Developmental and Epileptic Encephalopathies
DS Dravet SyndromeDup15 15q11-q13 dup lication syndrome
ECG Electrocardiogram
FSH Follicle stimulating hormoneCCICCIe
CCI
Property of Takeda: For NoMaM
CY
DIDI
DD-Commercial Use Only and Subject to the Applicable Terms of Usem time 0m time
from timfrom 
t quantifiu
Severity RSeverity
ncy dicy di sors
2019019
Federal Rederal
esterol 2terol 
onfidencnfiden
Non-C
Pr     Pr    CYPYP
DDIDDI
DD         s e         s em time m time 
rom tiom t
quantiquanti
everityverity
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 65 of 75
Protocol 23 August 2021
GCP Good Clinical Practice
GI Gastrointestinal
GMR Geometric mean ratio
HBsAg Hepatitis B surface antigenHCV Hepatitis C virus 
HIV Human immunodeficiency virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for HarmonizationIEC Independent Ethics Committee
INR International normalized ratio
IRB Institutional Review Board
LFT Liver function test
ln
Natural log
LGS Lennox Gastaut Syndrome
MedDRA®Medical Dictionary for Regulatory Activities®
NOAEL No-observed-adverse-effect-level
OATP organic-anion-transporting polypeptide
P-gp P-glycoprotein
PBPK Physiologicall y-based PK
PK Pharmacokinetic(s)PTE Pretreatment event
Q6H Every 6 hours 
QD Daily
QID Four times a day
QTcF QT interval corrected for pulse rate using Fridericia’s formulaRNA Ribonucleic acid
SAE Serious adverse event
SAP Statistical analysis plan
SOC Standard of care
SUSAR Sus
pected unex pected serious adverse reactions
TEAE Treatment-emergent adverse eventtmax Time of first occurrence of C
max
UGT Uridine diphosphate glucuronosyltransferaseULN Upper limit of normal
US United States
USA United States of America
CCICCIe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usevitiesvities
peptide d
mes a dayes a d
interval interva
Ribonucibonu
SerioSer
S
ax
UGT
ULNULN
Ukeda
Pr   Pr   ax
UGTUGT
ULUL             s e         s eitiesties®®
eptideptide
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 66of 75
Protocol 23 August 2021
15.0 DATA HANDLING AND RE CORD KEEPING
The full details of procedures for data handling will be documented in the Data Management P lan. 
AEs, m edical history , and concurrent conditions will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Drugs will be coded using the World Healt h Organizat ion Drug 
Dictionary.
15.1 CRFs (Electronic and Paper)
Celeri on standard CRFs will be supplied. CRFs are produced, stored electronically, and are 
available to the designated study  team  members. Each CRF is reviewed and signed by the 
Invest igator. The final signed CRFs are provided to the Sponsor in the format as decided upon 
between Celeri on and the Sponsor (eg, CD, flashdrive, SFTP). This will be documented in the 
Data Management Plan (if applicable).
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the CRFs for completeness and accuracy and must sign and 
date the appropr iate CRFs as indicated. Furthermore, the invest igator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the CRFs .
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the CRFs should be made by the investigator with use of change and modificat ion records of the 
CRFs. The principal invest igator must review the data change for completeness and accuracy, and 
must si gn and date . 
CRFs will be reviewed for completeness an d acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The Sponsor or i ts desi gnee will  be permi tted to revi ew the parti cipant’s 
medical and hospital records pertinent to the study to ensure accuracy of the CRFs. The completed 
CRFs are the sol
e property  of the Sponsor and should not be made available in any  form to thi rd 
parties, except for authorized representatives of appropriate governmental health or regulatory  
authorities, wi thout wri tten permissio n of the Sponsor.
15.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific docum ents, the i dentificat ion log of all 
participat ing participants, medical records, temporary media such as thermal sensit ive paper, 
source worksheets, all original signed and dated ICFs, participant authorizat ion forms regarding 
the use of personal healt h information (if separate fro m the ICFs), el ectroni c copy  of CRFs, 
including the audit trail, and detailed records of drug disposit ion to enable evaluat ions or audits 
from regulatory  authori ties, the Sponsor or i ts designees. Any  source documentati on prin ted on 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK-935)
Study No. TAK-935- 1007 Page 67 of 75
Protocol 23 August 2021
degradable thermal sensitive paper should be photocopied by the site and filed with the original in 
the participant’s chart to ensure long-term le gibility. Furthermore, ICH E6 Section 4.9.5 requires 
the investigator to retain essential documents specified in ICH E6 (Section 8) until at least 2 years 
after the last approval of a marketing application for a specified drug indication being investigated 
or, if an application is not approved, until at least 2 years after the investigation is discontinued and 
regulatory authorities are notified. In addition, ICH E6 Section 4.9.5 states that the study records 
should be r etained until an amount of time specified by applicable regulatory requirements or for a 
time specified in the Clinical Study Site Agreement between the investigator and Sponsor.
Refer to the Clinical Study Site Agreement for the Sponsor’s requirements on record retention. 
The investigator and the head of the institut ion should contact and receive written approval from 
the Sponsor before disposing of any such documents.
16.0 REFERENCES
1. Kupper, L. L. and Hafner, K.B., How appropriate are popular sample size formulas? Am Stat, 
1989. 43(2): 101-105.
2. TAK-935. Takeda Phar maceutical Company Ltd. Global Investigator’s Brochure. Edition 6, 
15 January 2021.
3. Sporanox®(itraconazole) oral solution 10 mg/mL, product monograph. Janssen 
Pharmaceuticals, Inc. website (document revised: 04/2019). Available at: 
http://www.janssenlabels.com/package-insert/product-monograph/prescribinginformation/SP
ORANOX-Oral+Solution-pi.pdf. 
4. Isoherranen N, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab 
Dispos. 2004;32(10):1121-31.
5. Ponstel®(mefenamic acid) capsules, Full prescribi ng information (electronic monograph; 
document revised 04/2021). Available at 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/015034s045lbl.pdf 
6. Food and Drug Administration: Drug Development and Drug Interactions: Table of 
Substrates, Inhibitors, and Inducers. (26 September 2016). Available at: 
https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteracti
onslabeling/ucm093664.htm.
7. Kasichayanula, S., et al., Effects of rifampin and mefenamic acid on the pharmacokinetics and 
pharmacodynamics of dapagliflozin. Diabetes Obes Metab, 2013. 15(3):280-3.
8. Callegari, E., et al., PhysiologicallyBased Pharmacokinetic Modeling of the Drug–Drug 
Interaction of the UGT Substrate Ertugliflozi n Following CoAdministration with the UGT 
Inhibitor Mefenamic Acid. CPT Pharmacometr ics Syst Pharmacol, 2021. 10(2):127-136.
9. Chen et al. Recommendations for the Design of Clinical Drug–Drug Interaction Studies With 
Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Mode CPT 
Pharmacometrics Syst. Pharmacol. (2019) 8, 685–695;e
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Users 
gated t
ued dand
dyyrecordrecyy
ments orment
Sponsopon
n record ecord
written written
ular samlar sa
lobal Inobal 
g/mL, p/mL,
revisedevis
insert/inse
aconazoonaz
.
d) capsud) cap
2021). A021). 
sdata.fddata.fd
g AdminAdmi
InhibitoInhibi
ww.fda.d
beling/ung/u
asichayaasicha
pharmpharm
8. CaC
Pr    Pr    g AA
InhibitInhibi
ww.fdaww.fd
beling/ueling/u
asichayasicha
pharmpharm
8. C8. C          s e         s es
ated ted 
ed ed andand
yrecoreco
ments oents o
Sponsopons
recordrecord
writtenwritten
ar samar sam
obal Iobal 
/mL, /mL
evisedevise
insertinse
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 68of 75
Protocol 23 August 2021
17.0 APPENDICES
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the Sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial participants, pri or to the recei pt of  
written approval  from relevant governing bodies/authorities.
5.Ensure th at all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to participants. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each pa rticipant who parti cipates in the study , and 
docum ent the date of consent in the participant’s medical chart. Valid informed consent is the 
most current versi on approved by  the IRB/IEC. Each ICF should contain a participant 
authori zation sect ion that descr ibes the uses and disclosures of a participant’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an ICF does not i nclude such a participant authorizat ion, then the invest igator must 
obtain a separate participant authorization form from each participant or the participant’s 
legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
CRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum of 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 69of 75
Protocol 23 August 2021
2years fo llowing notificat ion by the Sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receiv e wri tten approval  from the Sponsor before disposing of any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of Sponsor -supplied 
drugs, and return all unused Sponsor -supplied drugs to the Sponsor. 
13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 70of 75
Protocol 23 August 2021
Appendix B Elements of the P articipant Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each participant:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the participant ’s participation.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of participants invo lved in the study .
7.A descript ion of the participant’s resp onsibili ties.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the participant may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the participant and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the partici pant or to others that reasonably may  be expected 
from the research. W hen there is no intended clinical benefit to the participant, the participant 
shoul d be made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the participant and their important potential risks and benefit s.
14.A statement describing the extent to which confident iality of records i dentifying the 
participant will be maintained, and a note of the possibilit y that regulatory agencies, auditor(s), 
IRB/IEC, and the monitor may inspect th e records. By signing a written ICF, the participant or 
the participant’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to wh ether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the participant for participat ing in the study.
17.The ant icipated expenses, if any , to the parti cipant for parti cipating in the study .
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), participant’s rights, and IRB/IEC and whom to contact in the event of a 
research -related injury to the participant.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the parti cipant otherwi se is ent itled, and that the participant or the 
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 71of 75
Protocol 23 August 2021
participant’s l egally acce ptable representative may discont inue participat ion at any  time 
without penal ty or loss of benefit s to whi ch the parti cipant is otherwise ent itled.
20.The consequences o f a participant’s decisio n to withdraw fro m the research and procedures for 
orderly terminat ion of part icipation by the participant.
21.A statement that the participant or the participant’s legally  acceptable representative will be 
inform ed in a t imely manner if informat ion beco mes available that may be relevant to the 
participant’s willingness to continue participation in the study.
22.The foreseeable circumstances or reasons under which the participant’s participat ion in the 
study  may be terminated.
23.A written partici pant authori zation (either contained within the ICF or provided as a separate 
docum ent) describing to the participant the contemplated and permissible uses and disclosures 
of the participant’s personal informat ion (including personal health informat ion) for purposes 
of conducting the study . The parti cipant authori zation must contain the f ollowing statem ents 
regarding the uses and disclo sures of the participant’s personal information:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
participants the sam e level  of protecti on as the d ata protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal hea lth informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that participants agree not to restrict the use and disclosure of their personal information 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted u se or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the participant’s ident ity will remain confidential in the event that study  resul ts are 
published.
24. Regular pregnancy tests will be performed throughout the s tudy for all  female parti cipants.
Pr               se
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 72of 75
Protocol 23 August 2021
25.Male parti cipants m ust use effective contraception (as defined in the informed consent) from 
signing the informed consent throughout the duration of the study and for 90 days after the last 
dose of study  drug . 
26.A statem entthat clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 73of 75
Protocol 23 August 2021
Appendix CInvestigator Consent to the Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the wo rld (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studi es.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, a nd communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the same chemical co mpound present in the study medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protec tion laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 74of 75
Protocol 23 August 2021
Appendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Participants 
From  signing of informed consent, throughout the duration of the study , and for 90 days after last 
dose of study  drug, non sterilized* male participants who are sexually act ive with a female partner 
of childbearing potential** must use barrier contraception (eg, condom with or without 
spermicidal cream or jelly). In addit ion, they  must be advised not to donate sperm during thi s 
period. Total  abst inence (no sexual intercourse) may  be considered an acceptable method of birth 
control  if it agrees wi th his preferred and usual lifestyle.
Female Participants and Their Male Partners
Only women of non -childbearing potential will be inc luded in this study . A female of 
non-childbearing potential, must have undergone one of the fo llowing sterilization procedures at 
least 6 m onths pri or to the first dosing:
–hysteroscopic sterilization;
–bilateral  tubal  ligation or bilateral  salpingectomy;
–hysterectomy;
–bilateral  oophorectomy;
or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and FSH serum 
levels consistent with postmenopausal status**. 
Definitions and Procedures for Contraception and Pregnancy Avoidance
Thefollow ing definitions apply for contraception and pregnancy avoidance procedures.
* Sterilized males should be at least 1 y ear post -bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or ha ve had bilateral  
orchi dectomy .
** A woman is considered a woman o f childbearing potential (WOCBP), ie, fertile, fo llowing 
menarche and unt il beco ming post -menopausal unless permanent ly sterile. Permanent sterilizat ion 
methods include hysterectomy, and bila teral oophorectomy . A postm enopausal  state i s defined as 
no menses for 12 months without an alternat ive medical cause. A high fo llicle st imulat ing 
horm one (FSH) l evel in the postm enopausal  range (FSH >40 IU/L) may  be used to confirm a 
post-menopausal state in younger wom en (eg, those <45 year old) or women who are not using 
horm onal contracepti on or horm onal replacement therapy. However, in the absence of 12 months 
of amenorrhea, a single FSH measurement is insufficient.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Soticlestat (TAK -935)
Study No. TAK -935-1007 Page 75of 75
Protocol 23 August 2021
General Guidance With Respect to the Avoidance of Pregnancy
Such guidance should include a reminder of the fo llowing:
Contraceptive requirements of the study .
Reasons for use of barrier methods (ie, condom) in males with pregnant partners.
Assessment of participant compliance through questions such as:
–Have you used the contraception consistent ly and correctly since the last visit ?
– H ave y ou forgotten to use contraception since the last visit ? 
Pregnancy
Women of childbearing potential will not be included in this study .
If any participant i s found to be pregnant during the study  she shoul d be wi thdrawn and any 
sponsor -supplied drug should be immediately discontinued. In addit ion, any pregnancies in the 
partner of a male participant during the study  or for 90 day safter the l ast dose, sh ould also be 
recorded fo llowing authori zation from the participant’s partner. 
If the female participant and/or female partner of a male participant agrees to the primary care 
physician being informed, the investigator should notify the primary care physic ian that the female 
participant/female partner of the participant was participating in a clinical study  at the tim e she 
became pregnant and provide details of the study  drug the partici pant received (blinded or 
unblinded, as applicable).
All pregnancies, i ncluding female partners of male participants, in participants on active study  
drug (including comparator, if applicable) will be followed up to final outcome, using the 
pregnancy form. Pregnancies will remain blinded to the study  team . The outcom e, includ ing any  
prem ature terminat ion, must be reported to the sponsor. An evaluat ion after the birth of the child 
will also be conducted.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use